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Abstract 
ABSTRACT 
Although olfactory ensheathing cells (OECs) are used to promote repair in the injured 
spinal cord, little is known of their phenotype in this environment. This study examined the 
effect of the injured spinal cord on OEC morphology and gene expression. For in situ 
experiments OECs were encapsulated in porous polymer tubes and implanted into the lesioned 
rat spinal cord. Adult male hooded Wistar rats (300-350g) were anaesthetised with isoflurane 
maintained at 2.5% with 100% 02 (0.5L/min). Lesions were made to the corticospinal tract at the 
level ofT7-T8 and OEC-filled capsules were inserted under the dura above the lesion. After one 
week animals were sacrificed and the capsules retrieved. Procedures were performed in 
accordance with NHMRC guidelines approved by the University of Tasmania Animal Ethics 
Committee. Morphological characteristics were examined using scanning electron microscopy 
(SEM) for which implanted and un-implanted capsules were cut into halves so as the inner 
surfaces could be viewed. Implanted capsules were filled with rounded OECs and extracellular 
matrix (ECM)-like matter. Although no cells with the morphology of cultured OECs were 
observed these may have been obscured by the abundant ECM. In the un-implanted capsules 
cells with morphology typical of cultured OECs were predominant and although some rounded 
cells were detected. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was 
used to analyse expression of Neuregulin-1 (Nrg-1) and Nogo in cultured OECs and 
encapsulated OECs both in culture and after implantation. Neuregulins are known mitogens and 
survival factors for central nervous system (CNS) cells whilst Nogo is an axonal growth 
regulator. For comparison transcripts were also examined in a number of other glial cell types. 
Similar to astrocytes (ASTs) and fibroblasts (FBs), OECs expressed various Nrg-1 subtypes 
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including neu Differentiation Factor (NDF), Glial Growth Factor (GGF) and Sensory and 
Motomeuron-derived Factor (SMDF) along with other splice variants including those containing 
the epidermal growth factor (EGF), a-EGF, P-EGF and secreted domains. After implantation, 
OECs increased expression of NDF and secreted Neuregulin and decreased expression of the 
other variants. Olfactory ensheathing cells, oligodendrocytes (OLGs) Schwann cells (SCs) and 
ASTs all expressed Nogo-A, -B and -ABC. OECs and OLGs were also immunopositive for 
Nogo-A protein. Unlike OLGs, OECs, SCs and ASTs expressed mRNA for the Nogo-66 
receptor (NgR) although the protein could not be detected by immunocytochemistry in OECs. 
Implantation of OECs resulted in an increase in Nogo-A and -B and a decrease in Nogo-ABC 
and the NgR. Taken together these results show that OEC phenotype in the lesion environment is 
different from their characteristic profile in culture. 
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CHAPTER ONE 
Introduction 
1.1. Injury in the Central Nervous System 
In contrast to the peripheral nervous system (PNS), neurons in the central nervous 
system (CNS) fail to regenerate after injury despite an initial sprouting response. After 
injury the segment of the axon distal to the injury degenerates via a process termed 
Wallerian degeneration and the debris is phagocytosed by activated macrophages and 
microglia (Stichel and Muller, 1998). Provided that the cell body survives, the proximal 
segment retracts and sprouts neurites that advance toward the lesion site (Guth, 1974). 
These newly formed neurites are usually transient and extend for on~y short distances 
before they arrest and degenerate or persist at the lesion site (David and Aguayo, 1981 ). 
This initial sprouting response suggests that the failure of CNS neurons to regenerate is 
not intrinsic to the neurons themselves but is more likely to be a function of the 
inhospitable CNS environment. In fact this phenomenon was clearly demonstrated by 
Aguayo and colleagues who showed that CNS axons could extend neurites over long 
distances when exposed to peripheral nervous tissue but when in contact with CNS tissue 
their growth terminated abruptly (Richardson et al., 1980; David and Aguayo, 1981). 
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1.2. Inhibitors of Neurite Regeneration in the Central Nervous System 
It is now known that the CNS environment is hostile to axonal growth due to the 
presence of a variety of factors that actively inhibit neuronal growth. Some of these are 
considered below. 
1.2.1. The Glial Scar 
One of the major barriers to successful regeneration in the CNS is the inhibitory 
nature of the glial environment. Injury to the CNS results in the rapid activation of non-
neuronal cells at the lesion site resulting in what is known as a glial scar. A large 
proportion of the glial scar is composed of tightly interwoven astrocyte processes which 
are surrounded by extracellular matrix (Reier and Houle, 1988). Reactive astrocytes 
(ASTs) are characterised by rapid proliferation, hypertrophy and upregulation of glial 
fibrillary acidic protein (GFAP) (Latov et al., 1979; Mathewson and Berry, 1985; Vijayan 
et al., 1990). Several in vivo studies have highlighted the extremely inhibitory nature of 
the glial scar (McKeon et al., 1991; Bahr et al., 1995; Davies et al., 1996). Whether the 
glial scar is inhibitory because it creates a physical or chemical barrier to neuronal growth 
is being investigated. However it is known is that reactive ASTs express molecules such 
as tenascin-C, neurocan, brevican, NG2 and chondroitin sulphate proteoglycans (CSPGs) 
which are inhibitory to axonal growth (Levine, 1994; McKeon et al., 1995; Yamada et 
al., 1997; Asher et al., 2000). 
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1.2.2. Nogo 
CNS myelin and the surfaces of differentiated oligodendrocytes (OLGs) have long 
been associated with inhibition of neurite growth (Schwab and Caroni, 1988). CNS 
myelin contains two membrane bound proteins NI-35 and NI-250 (or Nogo) that are 
potent inhibitors of neurite outgrowth and fibroblast spreading in vitro (Caroni and 
Schwab, 1988b). A monoclonal antibody termed IN-1 raised against NI-250, was 
subsequently shown to neutralise the inhibitory action of NI-35/250 in vitro (Caroni and 
Schwab, 1988a). More importantly the same antibody also neutralized the inhibitory 
effects of NI-35/250 in viva (Schnell and Schwab, 1990). Not surprisingly the inhibitory 
nature of differentiated OLG surfaces could also be neutralized by IN-1 (Bandtlow et al., 
1990). Although it was clear from these early studies that IN-1 application could enhance 
neurite outgrowth no improvements in functional recovery were shown. Since then 
several reports have demonstrated varying degrees of functional recovery after 
application of IN-1 to various lesioned CNS tracts in the rat (Bregman et al., 1995; 
Thallmair et al., 1998; Blochlinger et al., 2001; Merkler et al., 2001; Raineteau et al., 
2001; Raineteau and Schwab, 2001; Bareyre et al., 2002), see Table 1.1 for a review. In 
addition, IN-1 promotes the growth of spared projections (Wenk et al., 1999) and 
sprouting of uninjured axons in the intact cerebellum (Buffo et al., 2000), suggesting a 
role for Nogo as a regulator of neuronal plasticity. 
The discovery of the bovine homologue of NI-250 termed bNI-220 (Spillmann et 
al., 1998) whose potent inhibitory action could also be neutralized by IN-1 led to the 
initial cloning of the IN-1 antigen, Nogo (Chen et al., 2000; GrandPre et al., 2000; 
Prinjha et al., 2000). The nogo gene encodes three major protein products, Nogo-A the 
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largest at 1163 amino acids, Nogo-B an intermediate splice variant at 360 amino acids 
and Nogo-C the smallest splice variant at 199 amino acids (Fig. 1.1). The three variants 
have a common C-terminal domain 188 amino acids long, Nogo-A and -B also have a 
common 172 amino acid N-terminal domain whilst Nogo-C has a truncated N-terminus 
(Chen et al., 2000). All three variants have two long hydrophobic membrane-spanning 
regions and an endoplasmic reticulum (ER) retention motif at their C-terminus. 
Nogo was also identified as a member of the reticulon (Rtn) protein family (Rtn-
4A) owing to its sequence homology with other Rtn family members (Grand.Pre et al., 
2000). Nogo has a 66 amino acid residue lumenal/extracellular domain similar to that 
found in Rtn 1, 2 and 3. The Nogo-66 domain was found to inhibit axon extension and 
induce growth con.e collapse in dorsal root ganglion (DRG) neurons. ln contrast the 66-
residue domains of Rtn 1, 2 and 3 do not inhibit neuronal regeneration (Grand.Pre et al., 
2000). Although the Nogo-66 domain was found to have inhibitory properties this did not 
discount the possibility that other domains may contribute to the inhibitory nature of 
Nogo. In a recent study of the Nogo-A protein, inhibitory activity was localized to three 
distinct sites including a region within the N-terminal domain, a Nogo-A specific region 
and the Nogo-66 C-terminal domain (Oertle et al., 2003b ). 
Of the major isoforms, Nogo-A is expressed mostly in the CNS where it has been 
localised to OLGs and some neurons (Chen et al., 2000), Nogo-B is expressed in 
neuronal and non-neuronal tissues (Chen et al., 2000; Grand.Pre et al., 2000; Huber et al., 
2002) and Nogo-C is largely expressed in muscle and to some extent in brain, kidney and 
liver (Chen et al., 2000; Grand.Pre et al., 2000; Huber et al., 2002). Restricted expression 
of Nogo-A in contrast to the ubiquitous expression of Nogo-B is thought to be due to 
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tissue-specific differential splicing (Oertle et al., 2003a). A complete overview of Nogo 
expression is given in Table 1.2. 
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A 
Human nogo 
10kb 
1Aa 1A 1D1E1F 1G 
Mouse nogo 
10kb 
1A 1D 2 
B 
1A 2 
1D 2 
3 
3 
3 
3 
1C 4 6 78 9 
1C 4 5 6 78 9 
4 5 8 7 8 
RTN-4A, Noga-A 
RTN-492, Foocen-m2 
RTN-491, Nogo-9 
~ ~ ~ r-1 ll ll IJ------. RTN-4C, Nogo-C 
RTN-4D 
hRTN-4E/Aa/Ab/F/G 
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FIGURE 1.1. Gene structure of human and mouse nogo!Rtn4. 
(A) The human nogo gene has 9 known exons and eight start sites (arrow heads) under the control of 
two separate promoters (Pl and P2). The mouse gene is comprised of 9 exons with 5 start sites under the 
control of the Pl and P2 promoters (Oertle et al., 2003a). Nogo-A/B transcription is regulated by the Pl 
promoter while Nogo-C is regulated by P2 (Oertle et al., 2003a). Exons 1 and 3 have been shown to be 
inhibitory for 3T3 fibroblast spreading in vitro and the middle part of exon 3 (found only in Nogo-A) 
potently inhibits neurite outgrowth from retinal ganglion cells, cerebellar granule cells, dorsal root ganglion 
(DRG) cells and PC12 cells. Exons 4 and 5 code for the loop-region termed Nogo-66, involved in DRG 
growth cone collapse (Oertle et al., 2003a). The second hydrophobic domain has a leucine-zipper like motif 
and has been implicated in apoptosis induction in some cancer cells (Li et al., 2001). (B) Thei:e are ten 
known splice variants ofnogo including the major variants Nogo-A, -Band -C, the minor variant RTN4-B2 
and the testis specific variants RTN4-D, -E, -Aa, -Ab, -F and -G. Modified from (Oertle et al., 2003a):' 
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TABLE 1.1. IN-1 antibody treatment in models ofCNS injury. 
Reference 
(Schnell and 
Schwab, 1990) 
(Bregman et al., 
1995) 
(Schulz et al., 
1998) 
(von Meyenburg 
et al., 1998) 
(Z'Graggen 
al., 1998) 
et 
(Thallmair et al., 
1998) 
(Raineteau et al., 
1999) 
(Wenk et al., 
1999) 
(Oudega et al., 
2000) 
(Buffo et 
2000) 
(Blochlinger 
al., 2001) 
al., 
et 
(Raineteau et al., 
2001) 
(Merkler et al., 
2001) 
(Papadopoulos et 
al., 2002) 
(Bareyre et al., 
2002) 
Model 
Intracerebral IN-1 application 7-10 
days prior to complete transection of 
CST. 
Mid-thoracic bilateral dorsal column 
hemisection and injection of IN-1 
secreting hybridoma cells mto 
parietal cortex. 
Unilateral sensorimotor aspiration 
lesions of cortex plus grafts of 
embryonic neocortical tissue and 
IN-1 secreting hybridoma cells 
implanted 
Bilateral spmal cord hemisection, 2 
or 8 weeks after injury IN-1 
secreting hybridoma cells injected 
and NT-3 soaked gelfoam inserted 
into lesion site. 
uPT and injection of IN-1 secreting 
hybridoma cells 
Unilateral CST lesion in brainstem 
and IN-1 secreting hybridoma cells 
injected into cortex. 
uPT and injection of IN-1 secreting 
hybridoma cells. 
Unilateral motor cortex ablation and 
injection of IN-1 secreting 
hybridoma cells. 
Dorsolateral hem1section at T8 and 
sub-dural infusion of a recombinant 
IN-1 antibody fragment. 
Recombinant IN-1 fragment injected 
into intact cerebellum. 
uPT and injection of IN-1 secreting 
hybridoma cells into contralateral 
cortex. 
bPT and injection of IN-1 secreting 
hybridoma cells into left 
hippocampus. 
Dorsal hemisection and injection of 
IN-1 secreting hybridoma cells into 
hippocampus. 
Middle cerebral artery occlusion and 
injection of IN-1 secreting 
hybridoma cells posterior to lesion 
uPT and injection of IN-1 secreting 
hybridoma cells into hippocampus. 
Results 
Induced sprouting and long distance (ie. 7-1 lmm) 
elongation ofCST neurites after 2-3 weeks of injury. 
Increased growth of CST axons which persisted at the 
lesion site for 12 weeks after injury, accompanied by 
functional recovery in exercises dependant upon the CST. 
Increased cholinergic fibre growth into the grafts and 
increased density of grafts after 12 weeks. 
IN-1 treatment 2 weeks after mjury produced regenerating 
CST fibres reaching 2- l 1.4mm in length whereas IN- I 
treatment 8 weeks after injury resulted in sprouting up to 
2mm in length. 
Complete restoration of forelimb use in treated ammals, 
increase in corticopontine and corticorubral midline 
crossing sprouts. 
Increased sprouting of intact CST fibres was paralleled by 
functional improvements. 
Increased sprouting of lesioned CST fibres and collaterals 
and improved elongation of sprouts. 
Increased sprouting of spared projections into the 
unlesioned hemisphere. 
Increased growth of lesioned CST axons and collaterals, 
regenerating fibres reached lengths of 1.4 -9mm. 
Induced sprouting of uninjured Purkinje cell axons the 
effect of which was reversible. 
Increased sprouting and fibre rearrangement, sprouts 
formed synaptic contacts in ipsilateral and contralateral 
pontine nuclei. 
Increased collateral sprouting of rubrospinal tract and 
recovery of forelimb movement including a rapid EMG 
response. 
Improved locomotor recovery in a range of exercises. 
8 weeks after injury forelimb reaching task performance 
reached 80% of pre-lesion levels, collateral sprouting 
found in unles1oned hemisphere. 
Increased midline crossing collateral sprouts from intact 
CST, gene expression changes including upregulation of 
growth associated proteins, growth factors and receptors, 
guidance molecules and transcription factors and 
downregulation of immune response molecules. 
(Raineteau et al., bPT and injection of IN-1 secreting Reorganisation of uninjured RST, collateral sprouts 
2002) hybridoma cells into left side of the innervated ventral horn of spinal cord where they contacted 
hippocampus. motoneurons. 
(Emerick et al., Sensorimotor aspiration lesion on Intracortical microstimulation mapping of the uninjured 
2003) left side and injection of IN-1 cortical hemisphere revealed an increase in movement of 
secreting hybridoma cells into the lesion-impaired forelimb suggesting motor cortex 
hippocampus. reorganisation. 
1 Abbreviations include unilateral pyramidotomy (uPT), bilateral pyram1dotomy (bPT), corticospinal tract (CST), 
rubrospinal tract (RST), electromyography (EMG). 
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TABLE 1.2. Distribution ofNogo and Nogo-66 receptor (NgR) expression. 
Location Nogo-A Nogo-B Nogo-C NgR 
Spina/Cord +•+ +• +• 
White matter +-< 
Grey Matter + + 
lntennediate Grey + 
Dorsal horn + 
Ventral horn 
Dorsal root ganglion +• + -+ + + + 
Cortex (neocortex) +•+ +• +• 
Layer l molecular layer 
Layer ll external granular layer + + + + 
Layer III external pyramidal layer + + + + 
Layer IV internal granular layer + + + + 
Layer V internal pyramidal layer + + + + 
Layer VI multifonn layer + + +- + 
Hippocampal formation 
Subiculum + + 
Ammon's horn (pyramidal cell layer) - + + + 
Hippocampus + ++ + + 
Dentate gyms {2ule cell layer) + +- + + 
Brainstem 
Habenular nucleus + + + + + + 
Red nucleus + + 
Pontine nuclei + 
Hypoglossal nuclei + + 
Reticular fonnation + 
Vestibular nuclei + 
Amygdala + + + + 
Pirifonn cortex ++ + + 
Thalamus + 
Hy~thalamus + 
Cerebellar Cortex +•+ 
Purk:inje cell layer - ++ 
Granular cell layer ++ + + + 
Molecular layer ++ + 
Olfaclory Bulb +••+ 
Mitral cell layer + 
Eye 
Optic nerve -1- + -1- + + + -+ + + 
Retina + + 
Peripheral Nerves 
Sciatic nerve + + + + + + t- + 
Non-neuronal Cells 
Schwann cells 
Astrocytes 
Oligodendrocytes + + + + -1-
Ependymal cells 
Microglia 
Adi~cY!es + 
Other Tissues 
Skeletal muscle +• - + + 
Testis + + 
Heart + + + + 
Lung ++ ++ 
Liver + ... 
Spleen ++ ++ 
Kidney ++ ++ 
Cartilage + + 
Skin + + 
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All data presented within this table represent rat and mouse tissues only. The (+) or (- ) signs indicate 
positive or negative expression respectively. Absence of a sign indicates that the authors either did not 
investigate that region, tissue and/or cell type, or that no data were reported. The presence of(*) indicates 
that the isoform was detected in feta! tissue and (8) is where the specific location of the isoform within the 
given region was unspecified. Each sign is colour-coded as follows depending on the reference from which 
the data were sourced; (Chen et al., 2000), (GrandPre et al., 2000), (Huber et al., 2002), (Hunt et al., 2002), 
(Jin et al., 2003), (Josephson et al., 2001 ), (Josephson et al., 2002) and (Liu et al. , 2002b ). The occasional 
discrepancies in expression data shown here may have resulted from the differences in detection techniques 
used in these studies. 
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1.2.2.1. The Nogo-66 Receptor 
To elicit its inhibitory effects the Nogo-66 domain interacts with a cell surface 
receptor termed the Nogo-66 receptor (NgR) (Fournier et al., 2001). The NgR is a high 
affinity glycophosphatidylinositol (GPl)-linked protein that contains a signal sequence, 
eight leucine-rich repeat (LRR) motifs and a cysteine rich LRR carboxy-terminal 
(LRRCT) flanking domain. The NgR has been localized to the surfaces of axons but is 
not found in OLGs. Cleavage of this receptor from the axonal surface renders neurons 
insensitive to Nogo-66 inhibition. Furthermore induction of NgR expression is sufficient 
to impart Nogo-66 responsiveness to previously unresponsive neurons (Fournier et al., 
2001). 
The NgR is largely expressed in brain and spinal cord although it has been detected 
in the olfactory bulb and heart (Hunt et al., 2002; Josephson et al., 2002) (refer to Table 
1.2 for an overview of NgR expression). Recently two proteins structurally and 
biochemically similar to the NgR termed NgRHl and NgRH2 were identified (Pignot et 
al., 2003). Together with NgR these molecules may represent members of a novel 
receptor protein family. NgRHl and NgRH2 could also potentially bind uncharacterised 
inhibitors of neurite outgrowth. 
1.2.2.2. OMgp and MAG Signaling via the NgR 
Oligodendrocyte-myelin glycoprotein (OMgp) is another CNS myelin protein that 
inhibits neurite outgrowth. OMgp is a GPI-linked protein containing a leucine rich repeat 
(LRR) domain which is sufficient to bind the NgR (Wang et al., 2002b). Evidence for this 
came from the demonstration that cleavage of the NgR from the surfaces of DRG axons 
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renders them insensitive to OMgp whilst addition of exogenous NgR confers OMgp 
responsiveness to insensitive neurons (Wang et al., 2002b). 
Myelin-associated glycoprotein (MAG) was also found to bind with high affinity to 
the NgR suggesting that NgR is necessary for MAG inhibition of neurite outgrowth. 
Hence cleavage of GPI-linked proteins from the axonal surface protects growth cones 
from MAG-induced collapse. Similarly MAG-resistant embryonic neurons are rendered 
MAG-sensitive by expression of NgR (Liu et al., 2002a). 
Although Nogo-66, MAG and OMpg share no sequence similarities their apparent 
ability to compete for binding sites on the same receptor suggested that they may share 
structural similarities. Competition for the same receptor may also explain the 
redundancy observed when the action of a single inhibitory component is blocked in vivo 
(e.g. only moderate improvements in neurite outgrowth are achieved by blocking MAG, 
Nogo-66 or OMgp individually). Hence the effects of these three neurite growth 
inhibitors could potentially be blocked by developing an effective antagonist of the NgR 
derived from any one of the three NgR ligands already identified (Domeniconi et al., 
2002). 
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1.2.2.3. Mechanisms of NgR Function 
To elucidate the mechanisms involved m NgR function each domain was 
investigated for its involvement in Nogo binding and inhibition (Fournier et al., 2002). 
Deletions in any individual LRR region resulted in a lack of binding perhaps due to 
disruption of tertiary structure. The NgR C-terminal (NgRCT) domain appeared not to be 
required for Nogo binding but was necessary for inhibitory signaling. Therefore the CT 
domain could facilitate NgR conformational changes leading to axon inhibition by the 
LRR domain. The NgR GPI domain was also found not to be directly involved in NgR 
signaling but alternatively could play a modulatory role. It has also been proposed that 
the GPI domain provides a cleavage site for the NgR. A truncated NgR protein termed 
NgREcto, lacking the NgRCT and GPI linkage domain antagonizes Nogo and a 
significant proportion of myelin-dependant inhibition both as a bound substrate and a 
soluble protein. However NgREcto was unable to overcome the inhibitory activity of 
CSPG/aggrecan suggesting that the protein acts specifically on the NgR pathway 
(Fournier et al., 2002). 
1.2.2.4. The p75NTR as a Co-receptor for the NgR 
Since the NgR is GPI-linked to the cell surface by analogy with other similarly 
anchored receptors it is likely that it associates with a transmembrane signal-transducing 
peptide. In fact the co-receptor for NgR was recently shown to be the p75 neurotrophin 
receptor (p75NTR) (Wong et al., 2002). Evidence for this came from a study in which an 
antibody raised against the p75NTR abolished the repulsive turning of growth cones 
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induced by a MAG gradient (Wong et al., 2002). In a later study a truncated p75NTR 
protein lacking the signal transducing intracellular domain was shown to block the 
inhibitory properties ofNogo-66, MAG, OMgP and CNS myelin suggesting that p75NTR 
mediates inhibitory signals through its interaction with the NgR (Wang et al., 2002a). 
Furthermore immunostaining revealed extensive co-expression of the NgR and p75NTR in 
the developing nervous system of the rat providing further evidence for a functional 
interaction between these two receptors. 
1.2.3. Myelin-Associated Glycoprotein 
Myelin-associated glycoprotein (MAG or siglec 4a) is a well known myelin-derived 
inhibitor of neurite outgrowth (McK~rracher et al., 1994; Mukhopadhyay et al., 1994). 
However its inhibitory activity was discovered long after it was initially cloned (Arquint 
et al., 1987). Interestingly MAGs inhibitory activity is mediated by a developmental 
switch in the neuronal response. For example MAG promotes the growth of embryonic 
neurons but inhibits the growth of postnatal and adult neurons (DeBellard et al., 1996). 
Moreover increasing the endogenous cAMP levels in adult neurons has been shown to 
override the growth inhibitory response to MAG (Cai et al., 2001). This may suggest that 
embryonic neurons have higher endogenous cAMP levels than adult neurons hence their 
ability to grow in the presence of MAG. 
MAG binds sialic acid residues on sialylated glycans and gangliosides (Kelm et al., 
1994; Vinson et al., 1996; Tang et al., 1997). MAG interacts directly with the sialylated 
gangliosides GTlb and GDla present on the surfaces of responsive neurons (Vinson et 
al., 2001; Vyas et al., 2002). Neuraminidase treatment which removes sialic acid from the 
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surfaces of neurons was therefore shown to block MAG inhibition, as were antibodies 
against GTlb and GDla (Vyas et al., 2002). Similarly a mutation in the sialic acid 
binding domain of MAG reduced the potency of its inhibito~ activity (Vinson et al., 
2001). Taken together these results suggest that GTlb and GD la act as functic~nal MAG 
receptors. 
It was later found that multivalent clustering of GT lb and GD la on the surfaces of 
neurons was sufficient for inhibition of neurite outgrowth on permissive substrates in the 
absence of inhibitory molecules (Vyas et al., 2002). This led to the theory that 
multivalent ganglioside clustering was perhaps an important first step in MAG associated 
neurite outgrowth inhibition, especially since GTlb and GDla lack an intracellular 
signaling domain. However GTlb was then shown to interact with p75NTR forming a 
receptor complex that transmits the inhibitory signal from MAG to neurons (Yamashita et 
al., 2002). Reports also suggest that MAG can signal via the NgR which requires p75NTR 
as a co-receptor (Domeniconi et al., 2002; Liu et al., 2002a). Recently MAG, GTlb, 
p75NTR and the NgR were localized to lipid rafts on the surfaces of neurons (Vinson et al., 
2003). Therefore raft-raft interactions on the surfaces of opposing cells could facilitate 
the interaction between MAG, its multiple receptors and downstream signaling 
components (Fig. 1.2). 
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Axon 
GT1b/GD1a,.,-
Nogo-66R / 
co-receptor 
Rho kinase 
FIGURE 1.2. Lipid-raft model of MAG and Nogo-66 signaling. 
21 
MAG 
p75 
Schematic representation of raft-raft interactions between axons and myelin-forming 
oligodendrocytes. Rafts are represented by blue/grey shading, MAG molecules in black, MAG receptors 
GTlb/GDla in red, p75 and NgR co-receptors in blue and associated signaling molecules in yellow. The 
localisation of MAG and its binding partners GTlb, GD la and the Nogo-66 receptor (NgR) within lipid 
rafts could provide discrete regions of high avidity interactions between the two cell types. Rafts may also 
provide a platform for multiple interactions involving MAG, its receptors and signaling molecules. 
Modified from (Vinson et al., 2003). 
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1.2.4. Rho Signaling by Myelin-Associated Inhibitors of Neurite Regeneration 
Intracellular signaling by MAG, Nogo and OMgp is known to involve the small 
GTPase Rho (Lehmann et al., 1999; Niederost et al., 2002; Yamashita et al., 2002; 
Fournier et al., 2003). In its active form Rho is bound to GTP but when inactive is bound 
to GDP. In the GTP-bound active state Rho family members regulate the assembly and 
stability of the actin cytoskeleton (Hall, 1994). Activation of Rho is therefore known to 
cause growth cone collapse and neurite inhibition (Kozma et al., 1997; Kranenburg et al., 
1999; Lehmann et al., 1999). Rho is maintained in an inactive state by Rho guanine 
nucleotide dissociation inhibitors (Rho-GDls). Rho-GDis are proteins that inhibit Rho 
activation by binding and sequestering Rho in the cytoplasm away from its targets in the 
cell membrane and blocking the binding of Rho to its substrates (Olofsson, 1999; 
Hoffman et al., 2000; Del Pozo et al., 2002). In a recent study it was found that p75NTR 
binds to Rho-GDI thereby displacing Rho from GDI allowing it to become activated 
(Yamashita and Tohyama, 2003). The resultant active Rho can then bind to and stimulate 
the activity of growth inhibitory proteins such as MAG, Nogo-66 and OMgp. Given that 
inhibitory signaling by these proteins converge on a common signaling pathway 
involving Rho this molecule could represent an important therapeutic target to overcome 
the barriers to neurite outgrowth in the CNS. 
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1.3. Use of Olfactory Ensheathing Cells in Promoting Repair in the 
Injured CNS 
Many strategies have been employed in the past to overcome the inhibitory nature 
of the CNS. One of the more successful techniques has been the use of cell 
transplantation therapy to stimulate neuronal survival and growth. Of the myriad of cell 
and tissue types used in transplantation studies one of the more promising ones in terms 
of regeneration and functional recovery has been the olfactory ensheathing cell (OEC). 
Here are described the origin, phenotype, growth promoting properties of these cells and 
their potential for transplantation mediated regeneration and remyelination. 
1.3.1. Origin of Olfactory Ensheathing Cells 
Olfactory ensheathing cells are derived from precursor cells in the olfactory 
epithelium. During development OECs migrate from the epithelium with the axon 
bundles they ensheath. Olfactory sensory neurons (OSNs) are continuously replaced from 
progenitor cells located in the olfactory epithelium of the nasal mucosa (Graziadei and 
Graziadei, 1979; Calof and Chikaraishi, 1989; Chuah and Au, 1991; Caggiano et al., 
1994). The axons of newly formed neurons cross from the peripheral to the central 
nervous system (PNS-CNS) where they form functional synapses with central neurons in 
specialised structures termed olfactory glomeruli in the olfactory bulb (OB) (Graziadei 
and Graziadei, 1979; Doucette et al., 1983). Even after transection of the olfactory nerves 
new neurons grow and form appropriate connections within the OB as demonstrated by 
structural studies using light microscopy (Graziadei and Graziadei, 1979; Doucette et al., 
1983). It is thought that OECs provide the necessary guidance and trophic support 
CHAPTER ONE: Introduction 24 
required by OSNs to make the correct connections within the glomeruli after transection 
(Tennent and Chuah, 1996; Chuah and West, 2002). Some of the growth promoting 
guidance molecules and neurotrophic factors expressed by OECs include laminin, N-
CAM, LI, Galectin-1 HSPG, and semaphorin 3A, FGF-1, FGF-2, PDGF, NGF, BDNF, 
NT-4/5, GDNF, NTN, CNTF and neuregulins (see review by Chuah and West). In this 
way OECs are considered to be at least partly responsible for.the apparent plasticity of 
the olfactory system (Doucette, 1990) which has since made them attractive candidates 
for transplant-mediated CNS repair. 
1.3.2. Phenotypic Properties and Plasticity 
It is now widely accepted that OECs share phenotypic characteristics in common 
with related glial cell types namely Schwann cells (SCs) and astrocytes (ASTs) 
(Doucette, 1990). In fact OECs have in the past been classified into two major groups; 
those with astrocyte-like properties and those with SC-like properties (Pixley, 1992; 
Franceschini and Barnett, 1996). Astrocyte-like OECs have a flattened morphology and 
express fibrous GFAP, embryonic neural cell adhesion molecule (EN-CAM) and low 
levels of p75NTR (Barber and Lindsay, 1982; Franceschini and Barnett, 1996). Schwann 
cell-like OECs have a spindle-like morphology, express p75NTR, diffuse GFAP and the 
major peripheral myelin protein P0 (Pixley, 1992; Franceschini and Barnett, 1996). 
However OECs can interchange between these two forms as the need arises which has 
led some authors to believe that OECs belong to a single malleable population that can 
exhibit a variety of phenotypic characteristics (Barber and Lindsay, 1982; Pixley, 1992; 
Doucette, 1995; Vincent et al., 2003). 
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However OECs have some characteristics that distinguish them from their closely 
related counterparts. Unlike SCs and ASTs, OECs are derived from the olfactory placode 
(Chuah and Au, 1991; Norgren et al., 1992). They exist almost exclusively in the outer 
olfactory nerve fibre layer (ONL) of the OB in the CNS and along the olfactory nerve in 
the PNS (Doucette, 1991, 1993). Olfactory ensheathing cells also contribute to the 
formation of the glia limitans (or glial limiting membrane) at the PNS-CNS boundary at 
the periphery of the olfactory bulb (Doucette, 1991 ). In embryonic animals the glia 
limitans is composed mostly of OECs. However after birth astroblasts are thought to 
migrate from deeper layers of the olfactory bulb into the glia limitans and differentiate 
into interfascicular astrocytes. 
1.3.3. Regulation of OEC Proliferation, Differentiation and Survival In Vitro 
Modulation of OEC biology is an extremely complex process and is only now 
beginning to be understood. Described below are some of the molecules known to 
regulator these processes in OECs in vitro. 
Heregulin (HRG) basic fibroblast growth factor (bFGF or FGF-2), platelet 
derived growth factor (PDGF) glial growth factor (GGF), insulin-like growth factor 1 
(IGF-1) and forskolin (FSK) are known to stimulate OEC proliferation in serum-
containing medium (Chuah and Teague, 1999; Chuah et al., 2000; Yan et al., 2001b). 
However in serum-free medium only FGF-2 and HRG were found to promote OEC 
proliferation (Yan et al., 2001b). 
The mitogenic effects of HRG, FGF-2, PDGF and IGF-1 OQ. OECs in serum-
containing medium can be enhanced by addition of the cyclic ( cAMP) elevating agent 
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FSK (Yan et al., 2001b). Similarly in serum-free medium the mitogenic effects of HRO 
and FOF-2 can be improved by addition of FSK (Yan et al., 2001b). Although FSK 
increases intracellular cAMP levels the mechanism by which this increase potentiates the 
effects of various growth factors in OECs is unclear. However FSK induced cAMP 
elevation enhances the proliferative reponse of Schwann cells (SCs) to PDGF by 
increasing expression of PDOF receptors (Weinmaster and Lemke, 1990). Therefore this 
could suggest that the synergistic proliferative effect of FSK and growth factors is related 
to cAMP-mediated receptor induction. 
Hepatocyte growth factor (HOF) was also found to enhance OEC proliferation in 
serum-free medium (Yan et al., 2001a). The proliferative effect of HOF on OECs was 
inhibited by FSK suggesting that HOF does not affect intracellular cAMP levels (Yan et 
al., 2001a). Similarly expression of the HOF receptor c-met remained unchanged after 
incubation of OECs with FSK (Yan et al., 2001a). Hence it appears that HOF enhanced 
proliferation in OECs is not associated with intracellular cAMP-mediated receptor 
induction. 
Lysophosphatidic acid (LP A) is a phospholipid that has been shown to enhance 
the proliferation and migration of OECs in vitro (Yan et al., 2003). LPA exerts its effects 
via the 0-protein-coupled receptors LPA1, LPA2 and LPA3, which are expressed by 
OECs (Yan et al., 2003). These cell surface receptors can mediate the downstream effects 
of LPA via activation of the; (1) Rho/Rho associated kinase (Rho/ROCK), (2) mitogen 
activated protein kinase/extracellular signal related kinase (MAPK/ERK) and/or (3) 
phosphoinositol 3-kinase (PI-3K) pathway. LPA induced proliferation and migration in 
OECs is blocked by inhibitors of the Rho/ROCK, MAPK/ERK and PI-3K pathways 
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suggesting involvement of these pathways in mediating the effects of LP A in OECs (Yan 
et al., 2003). Similarly inhibitors of the Rho/ROCK pathway were found to block LPA 
associated changes in morphology, F-actin assembly and the formation of focal adhesion 
complexes in OECs indicating a role for Rho/ROCK in cytoskeletal reorganisation and 
therefore migration (Yan et al., 2003). 
1.3.4. OECs Promote Axonal Growth 
Since OECs have the ability to promote growth in a system in which it occurs 
naturally it was thought that they may have the capacity to support growth in areas of the 
CNS where successful regeneration does not normally occur. This theory prompted the 
use of OEC transplants to enhance axonal growth in various regions of the nervous 
system including: the spinal cord (Ramon-Cueto and Nieto-Sampedro, 1994; Li et al., 
1997, 1998; Ramon-Cueto et al., 2000), brainstem (Gudino-Cabrera et al., 2000), fimbria-
fomix (Smale et al., 1996), hippocampus (Gudino-Cabrera and Nieto-Sampedro, 1996) 
and sciatic nerve (Verdu et al., 1999). A summary of studies using OECs_ ~o promote 
regeneration in the nervous system is given in Table 1.3. Many of these studies show 
improved axonal growth, elongation and sprouting in animals receiving OEC transplants 
(Ramon-Cueto and Nieto-Sampedro, 1994; Ramon-Cueto et al., 1998; Navarro et al., 
1999; Verdu et al., 1999). Similarly varying degrees of functional recovery have also 
been achieved with OEC implants (Li et al., 1997; Ramon-Cueto et al., 2000; Nash et al., 
2002a; Li et al., 2003). 
A recent study attempted to enhance the regenerative capacity of OECs by 
transfecting the cells with growth factor transgenes (Ruitenberg et al., 2002; Ruitenberg 
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et al., 2003). This study used adenoviral vectors to introduce the neurotrophin genes 
BDNF and/or NT-3 into OECs prior to implantation into the lesioned spinal cord of adult 
rats. The engineered cells were shown to reduce lesion volumes, increase sprouting and 
enhance hindlimb function when compared with normal OEC implants (Ruitenberg et al., 
2003). Since the engineered cells only transiently expressed the transfected genes perhaps 
stable transfection of OECs could further improve the regenerative outcome. 
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TABLE 1.3. Promoting regeneration in the nervous system using OEC-transplants. 
Reference 
(Ramon-Cueto 
and Nieto-
Sampedro, 
1994) 
Lesion and Transplantation Model Results 
Rhizotomy and transplantation of OECs into the 3 wks after injury axons re-entered the spmal cord. 
dorsal root entry zone (DREZ) 
(Lt et al., 1997) Corticopsinal tract transection and injection of OECs stimulated regeneration of cut CST axons through the 
(Ramon-Cueto 
et al., 1998) 
(Navarro et al., 
1999) 
(Verdu et al., 
1999) 
(Ramon-Cueto 
et al., 2000) 
(Lu et al., 
2002) 
(Verdu et al., 
2001) 
(Nash et al., 
2002b) 
(Li et al., 2003) 
(Verdu et al., 
2003) 
OECs 
Removal of a 4mm section of rat spinal cord. SC-
filled gmdance channel created a bridge between 
cord stumps. OECs injected into midline of both 
stumps. 
Injection of OECs into the DREZ after lumbar 
rhizotomy. 
Sciatic nerve transection and implantation of 
collagen-filled tubes containing OECs. 
lesion site and improved directed forepaw reachmg 
performance. 
OECs promoted long-distance growth of raphe and 
propriospmal neurons, axons grew through the graft and into 
the host tissue. OECs migrated longitudmally and laterally 
from the injection sites and also entered SC bridges. 
No major improvements seen after 14 days. After 60 days 
there were improvements in regeneration and functional 
reconnection of sensory fibres. 
79% of rats receiving collagen filled tubes plus OECs 
exhibited regeneration compared with 60% of rats with 
collagen tubes alone. 
Stereotaxic injections of OECs into completely 3-7 months post-surgery OEC transplanted animals 
transected rat spinal cords displayed locomotor recovery and regained sensorimotor 
reflexes. 
Olfactory lamina propria transplanted into 
transected spinal cord 4 weeks after imtial injury. 
Injection of OECs into photochemical lesion of 
the rat spinal cord. 
Methylprenisolone (MP) administered for 24 
hours post CST lesion and 1mplantatton of OECs 
OEC matrix transplant into hemisection lesions of 
the upper cervical spinal cord. 
10 wt;eks after implantation of lamina propria improved 
locomotor activity was observed. 
OECs reduced astrocytic ghosts and cystic cavitation during 
the first 15 days post-lesion. 
6 weeks after injury rats that received MP m addition to OEC 
transplants displayed improved axonal regrowth and 
functional recovery. 
2 months after injury improvements in supraspinal control of 
breathing had occurred. In the first 10-20 days after mjury 
OECs induced a rapid recovery of climbing skill, which 
remained stable over a period of 6 weeks. 
Injection of purified OECs after photochemical OECs prevented loss of spinal cord parenchyma and 
lesion of the spinal cord. improved functional outcome up to 3 months after injury. 
CHAPTER ONE: Introduction 30 
1.3.5. OEC Transplant-Mediated Remyelination 
Although OECs are normally non-myelinating they have the capacity to 
remyelinate demyelinated axons in vitro (Devon and Doucette, 1992) and in vivo 
(Franklin et al., 1996; Li et al., 1998; Barnett et al., 2000; Kato et al., 2000). 
Remyelination by OECs was found to be of a peripheral-type similar to that described for 
Schwann cells (Franklin et al., 1996; Kato et al., 2000). This is consistent with the finding 
that OECs express the peripheral myelin protein Po and the non-compact myelin protein 
2 '3 '-cyclic nucleotide 3 '-phosphodiesterase (CNPase) (Lee et al., 2001; Santos-Silva and 
Cavalcante, 2001). Olfactory ensheathing cells also express transcriptional factors and 
signalling molecules associated with the myelin formation pathway such as Krox-20, 
SCIP/Oct-6 and desert hedgehog (Dhh) (Smith et al., 2001). However there are 
conflicting reports regarding the presence of the major compact myelin component, 
myelin basic protein (MBP) in OECs (Doucette and Devon, 1994, 1995). This may be 
due to the fact that MBP expression in cultured OECs is highly dependent upon culture 
conditions (Doucette and Devon, 1994, 1995). 
Several in vivo studies have shown that OECs can remyelinate demyelinated axons 
in vivo a summary of which is given in Table 1.4. However remyelinating characteristics 
appear to be restricted to a distinct subset of cells. In one paticular study a range of OEC 
morphologies were observed after transplantation (Franklin et al., 1996). While a 
majority of transplanted cells assumed a SC-like myelinating phenotype there were some 
cells that associated with axons without forming myelin sheaths, while others did not 
associate with axons at all. From this study, it was unclear as to whether the non-
myelinating cells represented different morphological subsets of OECs or contaminating 
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cell types. In another study the presence of meningeal cell-like, SC-like and AST-like 
cells was detected following transplantation of a human OEC suspension (Barnett et al., 
2000). This suggested that the transplanted cells could exhibit a range of morphologies 
reflecting their tendency for phenotypic plasticity in culture. However the authors also 
stated that the meningeal cell-like population may have been a contaminating cell type 
which is possible, given that the human OECs used in this study were only 30-45% pure 
on the basis of p75NTR expression. Taken together these results demonstrate the need to 
develop a standardised set of characteristics that define OECs or to identify a new marker 
that is specific for OECs alone. 
One question directly emanating from the aforementioned studies was whether the 
purity of OEC transplants affected the ability of the cells to remyelinate axons. 
Interestingly one study showed that purified OECs selected by p75NTR expression 
produced less extensive remyelination than unpurified OEC populations (Lakatos et al., 
2003). The authors suggested that this could have been due to the presence of meningeal 
cells in the unpurified preparations. To determine if the presence of meningeal cells could 
improve remyelination by OECs a 70:30 mix of OECs and meningeal cells was injected 
into the demyelinated spinal cord. Indeed the resultant remyelination induced by the 
OEC/meningeal cell mix was more widespread compared with that produced by purified 
OECs suggesting that the remyelinating capacity of OECs may be profoundly affected by 
the purity of the cultures. 
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TABLE 1.4. OEC transplant-mediated remyelination studies. 
Reference 
(Franklin et 
al., 1996) 
(Imaizumi et 
al., 1998) 
(Li et al., 
1998) 
(Barnett et 
al., 2000) 
(Kato et al., 
2000) 
(Lakatos et 
al., 2003) 
Lesion and Transplantation Results 
Model 
OECs injected into sites of X-EB OECs formed peripheral type myelin sheaths around 
demyelinating lesions in the rat most demyelinated axons within 21 days. 
spinal cord. 
OECs injected into X-EB lesions of 21-25 days after OEC injection spinal cords were 
the dorsal columns in the rat 6 days removed and maintained in an in vitro recording 
after initial injury. chamber, remyelinated axons displayed enhanced 
conduction velocity. 
Electrolytic CST lesion 
injection of OEC suspension. 
and I week after injury OECs promoted sprouting of cut 
CST axons, 3 weeks after injury peripheral type 
remyelination of CST axons was observed, 
remyelinated fibres crossed the length of the lesion 
and re-entered the CST. 
Human OECs injected into X-EB Limited peripheral type remyelination occurred 3 
demyelinated lesions in the rat weeks after transplantation whilst at 6 weeks 
spinal cord. 
Compared human and rat OECs 
injected into X-EB demyelinated 
lesions in the rat spinal cord. 
remyelination was more widespread. 
3 weeks after transplantation of human or rat OECs 
extensive peripheral-type remyelination occurred. 
Injection of pure OECs, unpure After 3 weeks 3-fold greater remyelination occurred 
OECs or OEC/meningeal cell with unpurified OECs compared with pure OECs. 
suspension (70:30) after X-EB Similarly OEC/meningeal cell suspensions produced 
lesion of rat spinal cord. 3-fold greater remyelination compared with pure 
OECs. 
1 Abbreviations X-irradiated ethidium bromide (X-EB) lesion, corticospinal tract (CST). 
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1.3.6. The Effect of the Injured Spinal Cord on OECs 
The multitude of cytokines, proteoglycans and guidance factors upregulated after 
CNS injury, have the potential to modulate the biology of implanted OECs. Especially 
considering the degree of phenotypic plastiscity seen in OECs both in vitro and in vivo. 
Some of the more well characterised molecules found in the injured CNS and what is 
currently known of their effects on OEC biology are discussed here. 
The cytokines interferon y (IFNy) and basic fibroblast growth factor (FGF-2) play a 
major role after CNS injury in the induction of the glial scar. IFNy produced by activated 
T-lymphocytes increases the proliferation of astrocytes (ASTs) thereby enhancing 
formation of the glial scar (Yong et al., 1991 ). The effect of IFNy on OECs is unknown 
although its role as a mitogen for ASTs suggests that it may also have the potential to 
induce OEC proliferation. 
After injury to the brain and spinal cord FGF-2 is rapidly upregulated perhaps to 
initiate wound repair (Logan et al., 1992; Mocchetti et al., 1996). This increase in 
expression has been localised to neurons, macrophages, ASTs and endothelial cells 
(Logan et al., 1992). FGF-2 is a known mitogen for OECs in vitro (Chuah and Teague, 
1999) hence its upregulation in the injured spinal cord could promote proliferation of 
implanted OECs. 
Expression of transforming growth factor B (TGFB) has been shown to increase 
around the glial scar after spinal cord injury (Lagord et al., 2002). Upregulation of 
TGFBl expression occurs in the acute phase of injury where its presence is associated 
largely with neurons (Lagord et al., 2002). In contrast upregulation of TGFB2 expression 
occurs during the subacute phase and is localised to the vicinity of the wound in ASTs 
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and endothelial cells (Lagord et al., 2002). This pattern of expression may suggest that 
TGF~l modulates the inflammatory and neuronal response whilst TGF~2 regulates glial 
scarring. The effects elicited by TGF~ appear to depend on cell type. In ASTs TGF~l 
upregulates expression of glial fibrillary acidic protein (GF AP) a key indicator of reactive 
AST phenotype (Reilly et al., 1998), in SCs TGF~l and 2 enhance proliferation (Watabe 
et al., 1994), whilst in OLGs TGF~ induces apoptosis (Schuster et al., 2002). However 
the effect of TGF~ in modulating OEC biology has not yet been investigated. 
Tumor necrosis factor a (TNFa) is upregulated immediately after CNS injury. Its 
expression has been attributed to neurons, glial cells (including astrocytes, 
oligodendrocytes and microglia) and endothelial cells in the injured spinal cord (Yan et 
al., 2001c). Again the effect of this molecule on OECs is not known, yet these cells have 
recently been shown to express TROY a member of the TNF receptor superfamily 
(Hisaoka et al., 2004). Expression of this receptor could confer upon OECs the ability to 
respond to the TNF family of proteins. 
Lack of neurite growth in the injured CNS is also associated with increased levels 
of chondroitan sulphate proteoglycans (CSPG). These proteins are produced by reactive 
ASTs, OLGs and macrophages at the injury site (McKeon et al., 1991; Jones et al., 2002; 
Moon et al., 2002). The effects of these molecules on OECs are unknown and perhaps 
should be investigated. 
Breakdown of damaged oligodendrocytes and myelin at the injury site releases 
neurite growth inhibitors such as oligodendrocyte myelin glycoprotein (OMgp), myelin-
associated glycoprotein (MAG) and Nogo. Whilst the inhibitory effects of these 
molecules on neurite growth at the injury site have been characterised their effects on 
CHAPTER ONE: Introduction 35 
glial cells have not been reported. The potential for these factors to modulate OEC 
behaviour has not been investigated despite the fact that OECs posses the p75 
neurotrophin receptor (p75NTR), a co-receptor with the Nogo receptor (NgR) in OMgp, 
MAG and Nogo signalling (Wang et al., 2002a). It is possible since OECs express p75NTR 
that they also express the NgR, which could imply that they respond to OMgp, MAG and 
Nogo. Alternatively NgR could be used by OECs as a means of presenting inhibitory 
antigens to neurons as negative guidance cues. 
1.4. Properties of OECs that Promote Central Nervous Tissue Repair 
The regeneration promoting characteristics of OECs are thought to include their 
ability to successfully integrate into the host environment, the production of growth-
promoting soluble factors and the expression of membrane-associated proteins involved 
in cellular migration and guidance. Indeed each of these factors may be important for 
promoting CNS repair although perhaps not in isolation but in combination. 
1.4.1. Integration Within the Host Environment 
Although transplanted SCs have the ability to promote CNS regeneration and 
remyelination their capacity to do so is impeded by the presence of ASTs. In fact 
transplanted SCs migrate and survive poorly in the presence of ASTs resulting in limited 
remyelination capability (Iwashita et al., 2000). Since astrocytosis is a common feature of 
the CNS injury site the efficacy of SC transplants for promoting repair in these 
environments is questionable. In contrast several studies have shown that OECs not only 
survive transplantation into the injured spinal cord but that they can migrate unimpeded 
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through the host tissue unlike their SC counterparts (Ramon-Cueto and Nieto-Sampedro, 
1994; Ramon-Cueto et al., 1998; Ramon-Cueto et al., 2000). In one study OECs were 
transplanted into the lesion site in combination with SC-filled PAN/PVC guidance 
channels (Xu et al., 1997). Olfactory ensheathing cells moved freely through the glial 
scar, entered the SC-channel and invaded both spinal cord stumps. In contrast the SCs 
remained inside the channels and did not migrate. This may be partly due to the unique 
interactions between OECs and reactive ASTs. Several in vitro studies have demonstrated 
that OECs unlike SCs freely intermingle with ASTs, migrate into astrocytic areas and do 
not induce AST hypertrophy (Lakatos et al., 2000; Boruch et al., 2001; Van Den Pol, 
2003). Indeed OECs implanted into the photochemically damaged spinal cord can reduce 
astrocytic gliosis and cystic cavitation (Verdu et al., 2001). Taken together these results 
suggest that OECs may be capable of modifying the injury induced response of other 
glial cell types thereby counteracting the upregulation and/or release of growth restrictive 
molecules. 
1.4.2. Neurotrophic Factors 
Olfactory ensheathing cells produce a variety of neurotrophic factors that may 
enhance neuronal proliferation, differentiation and survival after transplantation. These 
factors belong to several distinct families some of which are described below. 
1.4.2.1. Neurotrophin Family 
The neurotrophin family consists of four members including nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and 
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neurotrophin-4/5 (NT-4/5). These factors have been shown to act as survival and 
differentiation factors for various neuronal populations. For example NGF (the 
neurotrophin family prototype) is a survival factor for cholinergic neurons in vitro 
(Hartikka and Hefti, 1988; Hatanaka et al., 1988) and in vivo (Hefti, 1986; Williams et 
al., 1986; Kromer, 1987; Gage et al., 1988) whilst BDNF, NT-3 and NT-4/5 enhance the 
survival and differentiation of striatal neurons (Mizuno et al., 1994; Ventimiglia et al., 
1995; Perez-Navarro et al., 1999). Olfactory ensheathing cells express several members 
of the neurotrophin family including; NGF, BDNF, and NT-4/5 (Boruch et al., 2001; 
Woodhall et al., 2001). Of these only NGF and BDNF are known to be secreted. 
The neurotrophin proteins interact with two classes of receptor; the high affinity 
tyrosine kinase (Trk) receptors and the low affinity p75NTR. The Trk receptors, TrkA, 
TrkB and TrkC confer ligand specificity for NGF, BDNFINT-415 and NT-3 respectively 
(Klein et al., 1991a; Klein et al., 199lb; Lamballe et al., 1991; Klein et al., 1992). The 
p75NTR receptor belongs to the tumor necrosis factor (TNF) family and lacks intrinsic 
catalytic activity (Chao, 1994). Although p75NTR is a common receptor for each of the 
neurotrophins (Rodriguez-Tebar et al., 1990; Dechant et al., 1997) NGF binding can 
uniquely activate a programmed cell death pathway (Dechant and Barde, 1997). The 
p75NTR is also an accepted marker for OECs in vitro and in vivo despite the fact that it is 
expressed by SCs. To date the only the high affinity neurotrophin receptor that has been 
localised to OECs is TrkB (Woodhall et al., 2001). 
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1.4.2.2. Neurotrophin-Related Factors 
Another closely related group of neurotrophic factors is the glial cell-line derived 
neurotrophic factor (GDNF) family of ligands (GFL) which form a subgroup within the 
transforming growth factor beta (TGF-~) superfamily (Kingsley, 1994). The members of 
this family include GDNF, artemin (ART), neurturin (NTN) and persephin (PSP) (Lin et 
al., 1993; Kotzbauer et al., 1996; Milbrandt et al., 1998; Airaksinen et al., 1999). GDNF 
is a known survival factor for dopaminergic neurons both in vivo (Lin et al., 1993) and in 
vitro (Lin et al., 1994; Meyer et al., 2000). Artemin is primarily a survival factor for 
sympathetic neurons but can also promote proliferation and act as a guidance factor 
(Baloh et al., 1998; Andres et al., 2001; Honma et al., 2002). Neurturin and PSP both 
promote survival of dopaminergic neurons (Horger et al., 1998; Milbrandt et al., 1998). 
Both GDNF and NTN mRNA have been detected in OECs (Woodhall et al., 2001). The 
GDNF protein is produced but it is not secreted by OECs, whilst the presence of NTN 
protein has not yet been investigated. 
The actions of the GFLs are mediated via members of the GDNF family receptor 
alpha (GFRa) group. GDNF, NTN, ART and PSP bind to GFRa-1 GFRa-2, GFRa-3 
and GFRa-4 respectively. Although these receptors confer ligand specificity they require 
the presence of the co-receptor RET for signal transduction (Trupp et al., 1996). Since 
OECs seemingly lack RET expression it is unlikely that GDNF and NTN could elicit 
intracellular signals within OECs (Woodhall et al., 2001). Nevertheless GFRa-1 and 2 
found in OECs could function to bind and present GDNF and NTN to growing neurons 
(Woodhall et al., 2001). GFRa-3 is also known to be expressed in embryonic but not 
adult olfactory epithelium and OECs (Widenfalk et al., 1998). The presence of its ligand 
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ART has recently been detected in embryonic and early postnatal OECs (Lipson et al., 
2003). 
1.4.2.3. Neuregulins 
In addition to the neurotrophins and related factors some neuregulin-1 (nrg-1) 
family members are expressed by OECs. The nrg-1 gene is located on the long arm of 
chromosome 8 and gives rise to multiple mRNA variants by way of alternative splicing 
and promoter usage (Orr-Urtreger et al., 1993) (Fig. 1.3). The nrg-1 proteins are derived 
from different combinations of the same structural domains and have been classified into 
3 major groups. Type I includes neu differentiation factor (NDF) or heregulin (HRG) and 
acetyl-choline receptor inducing activity (ARIA). These factors contain an 
immunoglobulin (lg)-like domain, epidermal growth factor (EGF)-like domain (a and p), 
a hydrophobic domain and an internal signal sequence for secretion (Falls et al., 1993). 
Type II or glial growth factors (GGF) contain a signal peptide, an lg-like domain an 
EGF-like domain (p) and a kringle-like sequence (Marchionni et al.,· 1993). Type III 
sensory and motor neuron derived factors (SMDF) have only a hydrophobic domain and 
an EGF-like domain (p) in common with other nrg-1 isoforms (Ho et al., 1995). The 
neuregulins are potent glial cell mitogens and survival factors (Pinkas-Kramarski et al., 
1994; Vartanian et al., 1994; Dong et al., 1995; Canoll et al., 1996; Grinspan et al., 1996). 
They are also crucial for PNS and CNS development (Lee et al., 1995; Gassmann and 
Lemke, 1997) and are important for neuromuscular synapse formation during cardiac 
development (Gassmann et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995). 
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In a recent study OECs were shown to express mRNA for NDF, GGF and SMDF 
(Thompson et al., 2000). Whilst mRNA encoding both membrane bound and secreted 
transcripts were detected the protein could not be located on the surface of the cells nor in 
concentrated conditioned medium. However the protein was detected in the nucleus or 
cytoplasm depending on the isoform suggesting a possible intracellular role for nrg-1 
proteins in OECs. 
The Nrg-1 receptors belong to the class 1 family of tryosine kinases termed erbB or 
epidermal growth factor (EGF) receptors. Members of this family ( erbB2, erbB3 and 
erbB4) form various homo- and hetero-dimeric complexes which can induce different 
biological responses depending on the activation of specific intracellular signal 
transduction pathways (Muthuswamy et al., 1999; Olayioye et al., 1999). Some studies 
suggest that OECs express erbB2 and erbB3 (Salehi-Ashtiani and ,Farbman, 1996; 
Perroteau et al., 1998), while others showed that OECs express erbB2 and erbB4, but not 
erbB3 (Pollock et al., 1999; Thompson et al., 2000). The apparent inconsistencies 
between these reports could either be due to culture conditions or differences in detection 
methods. 
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FIGURE 1.3. Putative representation of the neuregulin-1 (nrg-1) gene. 
The nrg-1 gene has fourteen exons (0-13), the structural domains that each exon represents is shown 
above (lg = immunoglobulin domain, glyco = glycosylation domain, EGF = epidermal growth factor a or p 
domain, JM = juxtamembrane domain and TM = transmembrane domain). Alternative splicing at the N-
terminal region of the gene produces Type I (NDF), Type II (GGF) and Type III (SMDF) nrg-1 subtypes. 
Further alternative splicing can occur in the EGF domain to produce a and p variants of each of the three 
subtypes. Other known splice variants include secreted and transmembrane variants. Modified from 
(Thompson et aL, 2000). 
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1.4.2.4. Other Growth Factors 
Ciliary neurotrophic factor (CNTF) is a member of the interleukin-6 neuropoietic 
cytokine (IL-6) family along with leukemia inhibitory factor (LIF), oncostatin-M (OSM), 
IL-11 and cardiotrophin-1 (Patterson, 1992; Ip and Yancopoulos, 1996; Murphy et al., 
1997). Each of these cytokines activates a different signalling protein that is anchored to 
the cell membrane via a GPI linkage. The lack of a transmembrane domain means that 
signal transduction requires a second receptor component, which is provided by gp 130 
(or IL-6 signal transducing glycoprotein 130). In the case of LIF and OSM the receptor 
complex is composed of the binding protein LIF receptor~ (LIFR~ or gp190) bound to 
the signal transducer gp130 (Gearing et al., 1991; Gearing and Bruce, 1992; Gearing et 
al., 1992). The IL-6 and IL-11 receptors are composed of the IL-6 receptor a (IL-6Ra or 
gp80) or IL-11 receptor a (IL-1 lRa) subunits similarly bound to gp130 (Yamasaki et al., 
1988; Murakami et al., 1993; Hilton et al., 1994; Yamasaki et al., 2001). However CNTF 
signalling involves the formation of a heterotrimeric complex initiated by binding of 
CNTF to its a receptor subunit (CNTFRa). The resultant CNTF/CNTFRa complex 
recruits the signal transducing binding partners gp130 and LIFR~ (Davis et al., 1991). 
Both CNTF and CNTFRa mRNA have been detected in OECs (Wewetzer et al., 
2001; Lipson et al., 2003). However another study failed to detect CNTF mRNA in OECs 
although this may have been due to the fact that their OECs were derived from a clonal 
cell line rather than primary culture (Boruch et al., 2001). 
LIF is thought to be a key mediator of injury-induced neurogenesis in the olfactory 
epithelium. Evidence for this comes from the observation that LIF and LIF receptor 
(LIFR) expression is upregulated after olfactory bulbectomy (Nan et al., 2001; Getchell et 
CHAPTER ONE: Introduction 43 
al., 2002; Bauer et al., 2003). This increase appears to coincide with the peak time for 
macrophage recruitment and the onset of progenitor cell proliferation after injury. 
Furthermore LIF has been localised to infiltrating macrophages and injured OSNs, whilst 
the LIFR has been detected in globose basal cells (GBCs) the immediate precursors of 
OSNs (Nan et al., 2001; Getchell et al., 2002; Bauer et al., 2003). Taken together these 
data suggest that LIF derived from infiltrating macrophages may function as a mitogen 
that stimulates proliferation of GBCs and that LIF produced by injured OSNs could act as 
an intracellular survival factor. Interestingly LIFR, IL-6 and IL-6R are upregulated in 
OECs after bulbectomy perhaps suggesting that these cells may play a role in OSN 
survival or repair after injury (Nan et al., 2001). 
The fibroblast growth factor (FGF) family consists of 18 known members (FGF-1 
to -18) (Ohbayashi et al., 1998). Acidic and basic fibroblast growth factor, FGF-1 and 
FGF-2 respectively were the first of these to be identified (Baird, 1994). The FGFs bind 
to the high affinity tyrosine kinase receptors FGFRl-4 of which there are seven known 
splice variants, including FGFR-lb, FGFR-lc, FGFR-2b, FGFR-2c, FGFR-3b, FGFR-3c 
and FGFR-4 (Ornitz et al., 1996). However to elicit their biological actions FGFs must 
also bind to a low affinity proteoglycan receptor on the cell surface (Yayon et al., 1991). 
Of the FGF ligands only FGF-1 and FGF-2 have been located in OECs and the 
olfactory nerve (Gall et al., 1994; Key et al., 1996; Chuah and Teague, 1999) although 
both ligands were also detected in distinct regions of the OB (Ernfors et al., 1990; 
Matsuyama et al., 1992; Key et al., 1996). In addition FGF-5 and -9 were detected in 
various regions of the OB but not in OECs (Gomez-Pinilla and Cotman, 1993; Tagashira 
et al., 1995). The receptors FGFRl-3 but not FGFR-4 were detected in the OB (Yazaki et 
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al., 1994). Olfactory ensheathing cells have also been shown to express FGFR-1 and 
perlecan (Chuah and Teague, 1999) a heparin sulphate proteoglycan known to be crucial 
for FGF binding and subsequent signalling events (Yayon et al., 1991). The presence of 
FGF-1 and -2 along with the FGFR-1 receptor and perlecan in OECs suggests that these 
cells could respond to FGFs in an autocrine manner. In fact FGF-1 and FGF-2 have been 
sh~wn to stimulate proliferation of OECs in vitro (Key et al., 1996; Chuah and Teague, 
1999). 
1.4.3. Cell Adhesion Molecules and Guidance Cues 
In addition to neurotrophic factors OECs express an array of adhesion and 
extracellular matrix (ECM) molecules that provide a permissive substrate for neurite 
extension, growth and migration. Many of these molecules play essential roles in 
development and may therefore be important in promoting CNS repair after injury. 
Described below are some of the various guidance factors expressed by OECs. 
Laminin has been localised to the axons of the olfactory nerve layer of the OB and 
to OECs (Liesi, 1985; Treloar et al., 1996): The spatiotemporal distribution pattern of 
laminin within the developing olfactory system suggests that it may function as a growth 
promoting molecule. In addition laminin appears to promote migration of olfactory axons 
from explant cultures of olfactory epithelium (Calof and Lander, 1991). Futhermore 
laminin facilitates the in vivo migration of OECs and increases their axon outgrowth 
promoting activity (Tisay and Key, 1999). Olfactory ensheathing cells also express neural 
cell adhesion molecule (N-CAM) and the Ll glycoprotein which are similarly expressed 
CHAPTER ONE: Introduction 45 
by olfactory axons (Miragall et al., 1989; Gong and Shipley, 1996). Both N-CAM and Ll 
mediate extension and fasciculation of olfactory axons during development. 
Galectin-1 is a carbohydrate binding protein expressed by OECs residing in the 
nerve fibre layer of the OB and in the olfactory nerve (St John and Key, 1999). This 
protein is thought to mediate sorting of olfactory axon subpopulations during 
development and to maintain specific glomerular connections postnatally. 
Neuroligin-3 is a homologue of the glial specific transmembrane adhesion molecule 
gliotactin which is crucial for the formation of the glial sheath in the PNS of Drosophila 
melanogaster (Gilbert et al., 2001). Neuroligin-3 is expressed by OECs, ASTs and SCs 
during development but is also found in mature OECs (Gilbert et al., 2001). By analogy 
with the function of gliotactin Neuroligin-3 in OECs could mediate the formation of 
cellular contacts or junctions between OECs and axons during ensheathment of olfactory 
nerve fascicles. The finding that mature OECs retain expression of Neuroligin-3 could 
reflect their capacity to retain some of their developmental characteristics, which aid 
neurite growth. 
Semaphorin 3A (Serna 3A) is a negative guidance cue that is differentially 
expressed by p75NTR positive OECs in the ONL of the OB (Schwarting et al., 2000). 
Serna 3A (or collapsin-1) is chemorepulsive for neuropilin-1 (npn-1) a receptor molecule 
found on the surfaces of some olfactory axons. In knockout mice lacking Serna 3A, npn-1 
positive axons entering the ONL are misrouted forming inappropriate connections within 
the glomeruli (Schwarting et al., 2000). Hence Serna 3A expressing OECs may help to 
guide subsets of npn-1 positive olfactory axons to their appropriate targets within the OB. 
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Given the roles of these proteins in guidance and elongation of axons and their 
presence in OECs it is conceivable that they may play an important role in the capacity of 
OECs to promote neurite growth in the CNS. 
1.5. Summary 
In summary OECs are a versatile cell type that can change morphology and 
antigenic profile as required. Since OECs share many characteristics in common with 
other glial cell types the search for a specific marker that will unequivocally distinguish 
these cells from their glial counterparts continues. It is well known that OECs promote 
axonal growth both in their natural environment and when transplanted into sites of CNS 
injury. Results of transplantation studies infer that the array of neurotrophic factors and 
cell adhesion molecules expressed by OECs in vitro and in vivo continue to be expressed 
by OECs when implanted into the injured CNS. However direct evidence supporting this 
characteristic is limited. Therefore the likelihood that OEC phenotype is altered by CNS 
injury associated molecules is an issue that should be addressed. As a result my 
hypotheses are: 
•!• Because OECs exhibit such diverse phenotypic characteristics depending 
upon culture conditions their morphology and antigenic profile will be 
affected by implantation into the injured CNS. 
•!• Specific isoforms of nrg-1 act as mitogens and survival factors for OECs in 
vitro and are known to change after olfactory nerve injury hence the profile of 
nrg-1 expression in OECs will change after implantation into sites of CNS 
CHAPTER ONE: Introduction 47 
injury, reflecting the antigenic plasticity of OECs and their potential to assume 
a regeneration specific phenotype. 
•!• Because Nogo and the NgR are commonly associated with axonal growth 
inhibition it is hypothesised that OECs in vitro and implanted into the injured 
spinal cord will express low levels ofNogo and NgR. 
1.6. Aims 
Hence the purpose of this study was to: 
•!• To investigate the morphology of encapsulated OECs in vitro and after 
implantation into the injured spinal cord by scanning electron microscopy. 
•!• To investigate Nrg-1 mRNA expression in cultured OECs compared with other 
cell types, and to determine if Nrg-1 mRNA expression in OECs is affected by 
the injured spinal cord. 
•!• To determine if cultured OECs express Nogo and NgR mRNA and the 
corresponding proteins, and to investigate whether Nogo expression is 
influenced by the injured spinal cord. 
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CHAPTER TWO 
General Materials and Methods 
All procedures involving animals were approved by the Animal Experimentation 
Ethics Committee of the University of Tasmania and are consistent with the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes. 
2.1. Cell Cultures 
2.1.1. OEC Culture 
Primary OEC cultures were prepared as described previously (Chuah and Teague, 
1999; Woodhall et al., 2001). Briefly ten 1-2 day old hooded Wist~r rat pups were 
anaesthetised and their olfactory bulbs dissected out. The ONL of each bulb was removed 
and digested in 0.09% trypsin and 0.25% collagenase diluted 1 :2 with Minimum 
Essential Eagle Medium Hepes modification (MEM-H) (3 x 15 minutes at 3 7°C) then 
filtered through nylon mesh (80µm pore size). After centrifugation for 10 minutes at 
500xg the cells were resuspended and plated into a 25cm2 flask. Cells were maintained in 
Minimum Essential Eagle Medium D-valine modification (MEM D-valine) (Life 
Technologies), containing 10% dialysed fetal calf serum (dFCS) and 1 % penicillin-
streptomycin-fungizone solution (Life Technologies) at 37°C, 5% C02. Contaminating 
fibroblasts were removed by addition of cytosine arabinofuranoside (2.5 x 10-7M) 
(Sigma). To enhance the proliferation of OECs, 125µg/ml bovine pituitary extract (BPE) 
(Sigma) was added to the cultures. Once sufficient confluency was obtained cells were 
passaged to a new flask by trypsinisation with 0.25% trypsin in Hank's Balanced Salt 
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Solution (HBSS). Cells were then grown for 3 days or until they reached confluency. To 
determine purity of the cultures cells were grown on 13mm diameter coverslips at a 
density of 1 x 104 per coverslip and immunostained with monoclonal anti-p75NTR 
(Chemicon) and monoclonal anti-glial fibrillary acidic protein (GF AP) diluted 1: 100. 
Cells were also counterstained with 0.01% Nuclear Yellow (Sigma Cat. No. N-2137). 
OECs were estimated to be 91 % p75NTR and 93% GFAP positive in serum containing 
medium (Fig. 2.1 ). 
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FIG URE 2.1. lmmunofluorescence of p75 TR in olfactory ensheathing cells (OECs). 
Immunostaining of OECs maintained in MEM D-valine with G-5 supplement (left) and MEM D-
valine with 10% dFCS (right). Cultures were estimated to be 91% p75NTR positive (A, B) and 93% GFAP 
positive (C, D). Cells were counterstained with Nuclear Yellow (E, F). Controls in which the primary 
antibodies were omitted were negative (G, H). Scale bar, 1 OOµm. 
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2.1.2. Astrocyte and Oligodendrocyte Culture 
2.1.2.1. Mixed Culture 
51 
Primary AST and oligodendrocyte (OLG) cultures were prepared from the cortices 
of 2 day old hooded Wistar rat pups and purified using a modification of a previously 
described method (McCarthy and De Vellis, 1980). Whole brain was dissected out and 
the meninges, cerebellum and brainstem removed. The tissue was placed in Minimum 
Essential Eagle Medium Hepes modification (MEM-H) (Sigma) then minced and 
triturated through a flame polished pasteur pipette and filtered through nylon mesh 
(80µm pore size). Cells were centrifuged at 500xg for 5 minutes and plated at a density 
of 1-2 x 107 cells per 75cm2 flask. Cultures were maintained in Dulbecco's Modified 
Eagle Medium/F-12 modification (DMEM/F-12) (Life Technologies) with 10% PCS and 
1 % penicillin-streptomycin-fungizone solution at 37°C and 5% C02• Medium was 
changed every 3 days until confluency was reached (7-9 days). The length of the initial 
culture period was held between 7 and 9 days as periods shorter than this are insufficient 
to obtain stratification of ASTs and OLGs whilst periods longer than this can result in the 
clustering of ASTs above the normal bedlayer (McCarthy and De Vellis, 1980). Due to 
the nature of the separation procedure these AST clusters can break up and contaminate 
the OLG preparation (McCarthy and De Vellis, 1980). Microglia were removed 
mechanically by shaking the flasks on a rotary shaker for 1 hour at 200 rpm. Medium was 
then replaced and the cultures were shaken for a further 18 hours at 180rpm to isolate the 
OLG precursors that grow on top of the AST bedlayer. 
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2.1.2.2. Purification of Astrocytes 
After the OLGs were removed ASTs were passaged by trypsinisation with 2.5% 
trypsin in lOml EDTA solution. Cells were centrifuged at 500xg for 5 minutes and 
resuspended in Dulbecco's Modified Eagle Medium (DMEM) (Sigma) with 10% FCS 
and 1 % penicillin-streptomycin-fungizone solution (Life Technologies). The cell 
suspension was plated into three 75cm2 flasks and grown to confluence at 37°C and 5% 
C02. For immunostaining cells were plated at a density of 1 x 104 per 13mm diameter 
coverslip. To determine the purity of AST cultures, cells were stained with mouse 
monoclonal anti-GF AP (Sigma) diluted 1: 100 and polyclonal rabbit anti-cow S-100 
(DAKO) diluted 1:100. Cells were also counterstained with 0.01% Nuclear Yellow C: 
(Sigma, Cat. No. N-2137). Astrocytes purified by this technique were estimated to be 
92% GFAP positive and 97% S-100 positive in serum-containing medium (Fig. 2.2). 
2.1.2.3. Purification ofOligodendrocytes 
The supernatant containing the OLGs was pelleted at 500xg for 10 minutes 
resuspended in DMEM containing 10% FCS and transferred to a 25cm2 flask. 
Oligodendrocytes were further purified by transferring the supernatant to a new 25cm2 
flask 45 minutes after initial plating. Since serum contains inducers and repressors of 
OLG differentiation, their maturation is favoured by low serum-containing medium. 
After an initial 24 hours in serum-containing medium the cells were rinsed three times 
with DMEM and fed with DMEM containing G-5 supplement and 50 ng/ml tri-
iodothyronine (T3). T3 was added to increase proliferation and differentiation of OLG 
progenitors. Cells were maintained at 3 7°C with 5% C02 until they reached confluency 
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(~10 days). For immunostaining cells were plated onto 13 mm diameter coverslips at a 
density of~ 1 x 104 cells per coverslip in DMEM with 10% FCS. After 24 hours the cells 
were rinsed three times with DMEM and the medium was changed to DMEM containing 
G-5 supplement and 50ng/ml tri-iodothyronine (T3). To determine the purity of OLG 
cultures cells were immunostained with monoclonal mouse anti-myelin/oligodendrocyte 
specific protein (MAB328) diluted 1:100 (Chemicon). Cells were counterstained with 
0.01 % Nuclear Yellow (Sigma, Cat. No. N-2137). Oligodendrocytes were estimated to be 
98% pure on the basis of MAB328 staining (Fig. 2.3). 
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FIGURE 2.2. Immunofluorescence for GFAP in astrocytes (ASTs). 
lmmunostaining of ASTs maintained in DMEM with G-5 supplement (left) and DMEM with 10% 
FCS (right). Cultures were estimated to be 92% GFAP positive (A, B) and 97% S-100 positive (C, D). 
Cells were counterstained with Nuclear Yellow (E, F).Controls in which the primary antibody was omitted 
were negative (G, H).Scale bars, lOOµm . 
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FIGURE 2.3. Immunofluorescence for MAB328 in cultured oligodendrocytes (OLGs). 
Immunostaining of OLGs maintained in DMEM with G-5 supplement and 50ng/ml T3 for the 
myelin associated marker MAB328. Cultures were estimated to be 98% MAB328 positive (A). Cells were 
counterstained with Nuclear Yellow (B). Controls where the primary antibody was omitted showed 
negative staining (C, D). Scale bars, lOOµm. 
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2.1.3. Fibroblast Culture 
Explant cultures of fibroblasts were prepared using skin dissected from the back of 
two day-old hooded Wistar rat pups. A lcm2 slice of skin was placed into a petri dish 
containing warmed O.lM phosphate buffered saline pH7.4 (PBS) and cut into small 
pieces. Explants of approximately 2mm2 were placed into a 50cm2 dish and maintained in 
DMEM (Sigma) containing 10% FCS, 200mM L-glutamine and 1 % penicillin-
streptomycin-fungizone solution. After about 7 days cells were passaged using 0.25% 
trypsin/EDTA solution and centrifuged at 250xg for 10 minutes. The pellet was 
resuspended in 20ml medium and distributed into two 75cm2 flasks. Cells were incubated 
at 37°C with 5% C02 and grown to-confluency. 
2.2. Immunohistochemistry and Cell Purity 
2.2.1. Immunostaining Procedure 
Cells on 13mm diameter coverslips were fixed with 4% paraformaldehyde for 15 
minutes at room temperature. After washing three times in PBS the cells were incubated 
with the appropriate primary antibodies diluted 1: 100 in PBS containing 1 % normal goat 
serum (NGS) overnight at 4°C. To provide negative controls cells were incubated with 
1 % NGS without primary antibody. Cells were rinsed three times and incubated with the 
appropriate secondary antibodies diluted 1:1000 in PBS containing 1 % NGS for 1 hour at 
room temperature. Cells were counterstained with 0.01 % Nuclear Yellow and mounted 
with DAKO® Fluorescent Mounting Medium. Staining was then examined by fluorescent 
microscopy using an Olympus BX50 microscope with the appropriate filters for the 
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fluorochromes conjugated to the secondary antibodies. Cells were imaged using the 
Olympus DP50 digital camera. 
2.2.2. Cell Counts 
All positive cells were scored at 20Qx magnification using the appropriate 
fluorescent filter for the fluorochromes conjugated to the secondary antibodies. The total 
number of cells per field of view was determined by counting the Nuclear Yellow 
positive cells. Coverslips were scanned and ten adjacent fields per coverslip were 
counted. The cell-labelling index was determined using the following equation: 
Cell-labelling index(%)=(# Specific antigen positive cells-+-# Nuclear yellow positive cells) x 100% 
2.3. Rat Brain Tissue Procurement 
Neonatal 1-2 day-old Hooded Wistar rat pups were sacrificed and their heads were 
removed. The cranium was dissected so as the whole brain could be retrieved. The 
meninges, olfactory bulbs and brainstem were removed and the remaining tissue was 
snap frozen in liquid nitrogen and stored at -80°C to be used for RNA extraction. 
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2.4. Total RNA Isolation and Quantitation 
2.4.1. RNA Isolation 
2.4.1.1. Monolayered Cells 
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Total RNA was isolated from all cultured cells using TRlzol Reagent according to 
the manufacturer's instructions (Life Technologies, Cat. No. 15596-026). To each culture 
flask, 1 Oml of TRlzol per 1 Ocm2 of flask area was added. Cells were detached from the 
flask using a cell scraper and allowed to sit for 2-3 minutes. The supernatant was then 
pipetted over the surface of the flask several times before being transferred to a corex 
tube. The sample was then incubated for 5 minutes at room temperature. To each sample 
0.2ml of chloroform per lml of TRlzol was added. Tubes were then shaken vigorously 
for 15 seconds and incubated at room temperature for a further 2-3 minutes. Samples 
were centrifuged at 12 OOOxg for 15 minutes at 4°C in a Sorvall RC5C (DuPont). The 
aqueous phase was then transferred to a new corex tube. To precipitate the RNA 0.5ml of 
isopropyl alcohol was added per lml of initial TRlzol volume. Samples were incubated at 
room temperature for 10 minutes and centrifuged at 12 OOOxg for 10 minutes at 4°C. The 
pellet was rinsed with 75% ethanol and centrifuged at 7 500xg for 5 minutes at 4°C. RNA 
samples were vacuum-dried for 5 minutes and redissolved in 20µ1 RNase-free water. 
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2.4.1.2. Encapsulated Cells 
RNA was extracted from encapsulated cells by a modification of the TRizol 
technique described in section 2.4.1.1. Capsules were placed in an eppendorf tube 
containing 800µ1 of TRizol reagent. To ensure that the cells were adequately exposed to 
the reagent capsules were minced and the solution triturated. Following 5 minutes 
incubation at room temperature 160µ1 of chloroform was added to each sample. The 
samples were shaken vigorously for 15 seconds and centrifuged at 12 OOOxg for 15 
minutes at 4°C. The supernatant was removed and placed into another eppendorftube. To 
improve the yield of RNA from the capsules lOµg of RNase-free glycogen (Life 
Technologies, Cat. No. 10814-010) was added to each sample to carry the RNA to the 
aqueous phase. To precipitate the RNA 400µ1 of isopropylalcohol was added to the 
supernatant and samples were incubated for 10 minutes at room temperature. Samples 
were then centrifuged at 7 500xg for 5 minutes at 4°C, vacuum-dried for 5 minutes and 
redissolved in 10µ1 of RNase-free water. 
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2.4.1.3. Rat Brain Tissue 
Total RNA from whole rat brain tissue was extracted using the RNeasy maxi kit 
(Qiagen). Approximately 0.25g of tissue per extraction was crushed in liquid nitrogen 
and homogenized in extraction buffer using an ultra-turrax. The homogenate was then 
applied to an RNeasy maxi-column and processed according to the manufacturer's 
protocol. RNA was eluted from the column in 100µ1 ofRNase-free water and stored at -
80°C. 
2.4.2. DNase-1 Treatment 
RNA samples were pretreated with DNase-1 (Sigma) to remove any genomic DNA 
contamination. For each sample a separate tube containing the following reaction 
components was prepared. 
•:• 1 µg RNA sample 
•:• 8µ1 RNase-free water 
•:• 1µ1 lOx Reaction buffer 
•:• lµl Amplification grade DNase-1 (1 U/µl) 
After 15 minutes incubation at room temperature 1µ1 of stop solution was added to 
each sample and tubes were heated to 70°C for 10 minutes. Treated samples were stored 
at -80°C. 
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2.4.3. RNA Quantitation and Purity 
A lµl aliquot of each total RNA sample was resuspended in 40µ1 of water, mixed 
and quantified spectrophotometrically at Az60· Measurements of RNA purity were 
determined in TE buffer in the same manner using the Az6o/ A2so ratio. Samples with 
ratios of 1.8-2.1 were considered pure. 
2.5. Media and Solutions 
All media and solutions for tissue culture were sterilised via a 0.22µm bottle top 
filtration system (Millipore). 
2.5.1. Cell Culture 
Dulbecco's Modified Eagle Medium (DMEM) 
Contents of sachet 13.4g (Sigma, Cat. No. 12100-046) plus 3.7g NaHC03 (Sigma, 
Cat.No. 5-5761) made up to one litre with distilled water (pH 7.2). 
DMEM with G-5 Supplement 
lml G-5 supplement (Life Technologies, Cat. No. 17503-012) 
lml penicillin-streptomycin-fungizone solution (CSL, Cat. No. 09291501) 
Made up to lOOml with DMEM (Sigma, Cat. No. 12100-046). 
Minimum Essential Eagle Medium D-valine Modification (MEM D-valine) 
Contents of one vial 9.6g (Sigma, Cat. No. M7395) plus 2.2g NaHC03 (Sigma, Cat. No. 
5-5761) made up to one litre with distilled water (pH 7.2) and filtered. 
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MEM D-valine with 10% dialysed Fetal Calf Serum (dFCS) 
lml of penicillin-streptomycin-fungizone solution (CSL, Cat. No. 09291501) 
lOml dFCS (Sigma, Cat. No.) 
Made up to lOOml with MEM D-valine (Sigma, Cat. No. M7395). 
Hanks Balanced Salt Solution (HBSS) 
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Contents of one vial 9.5g (Sigma, Cat. No. H-2387) plus 0.35g NaHC03 (Sigma, Cat. No. 
5-5761) made up to one litre with distilled water (pH 7.2). 
Minimum Essential Eagle Medium Hepes modification (MEM-H) 
Contents of one vial (Sigma, Cat. No. M-2645) plus 2.2g NaHC03 (Sigma, Cat. No. 5-
'5761) made up to one litre with distilled water (pH 7.2). 
Dulbeccos Modfied Eagle Medium/F-12 Modification CDMEM/F-12) 
Contents of one sachet 15.6g (Life Technologies, Cat. No. 12400-024) plus l.2g 
NaHC03 (Sigma, Cat. No. 5-5761) made up to one litre with distilled water (pH 7.2). 
DMEM/F-12 with 10% FCS 
lOml FCS (Life Technologies, Cat No.) 
lml penicillin-streptomycin-fungizone solution (CSL, Cat. No. 09291501) 
Made up to lOOml with DMEM/F-12 (Life Technologies, Cat. No. 12400-024). 
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Neurobasal with B-27 Supplement 
0.1 ml B-27 supplement (Life Technologies, Cat. No. 1704-044) made up to lOml in 
Neurobasal medium (Life Technologies, Cat. No. 21103-049). 
0.09% Trypsin and 0.25% Collagenase Solution 
0.009g trypsin (Life Technologies, Cat. No. 27250-042) 
0.025g collagenase (Sigma, Cat. No. C-9891) 
Made up to lOml with MEM-H (Sigma, Cat. No. M-2645) 
0.25% Trypsin Solution 
0.025g trypsin (Life Technologies, Cat. No. 27250-042) in lOml MEM-H (Sigma, Cat. 
No. M-2645). 
2.5% Trypsin Solution 
0.25g trypsin (Life Technologies, Cat. No. 27250-042) in lOml PBS 
Bovine Pituitary Extract (BPE) 
Contents of one vial 5mg (Sigma) in lml HBSS (Sigma, Cat. No. H-2387) to give a 
concentration of 5mg/ml divided into lQx aliquots of 100µ1 and frozen at -20°C. 
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2.5.2. Solutions 
2.5.2.1. RNA Extraction and RT-PCR 
TE Buffer (lOmM Tris-HCl; lmM EDTA) 
lml tris-HCl (pH7.4) (Sigma, Cat. No. T-3253) 
0.2ml 0.5M EDTA (BDH Analar) 
Made up to 1 OOml in distilled water and filtered. 
lOx TBE Buffer (lM Tris-base; lM boric acid; 20mM EDTA) 
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Dissolve 121g Tris-base (Sigma, Cat. No. T-6791), 61.7g boric acid (Sigma, Cat. No. B-
6768) and 7.44g EDTA (BDH Analar) in 800ml of distilled water (pH 8.0) and make up 
to one litre. 
1.5% Agarose 
1.5g agarose powder (Life Technologies, Cat. No. 15510-027) in lOOml lx TBE buffer. 
2.5.2.2. Scanning Electron Microscopy 
O.lM Phosphate Buffer (pH 7.2) 
68.4ml 1M Na2HP04 (Univar) 
31.6ml 1 M NaH2P04.2H20 (Univar) 
Made up to one litre with distilled water. 
lMNa2HP04 
14.2g Na2HP04 (Univar) in lOOml distilled water 
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IM NaH2P04.2H20 
15.6g NaH2P04.2H20 (Univar) in lOOml distilled water 
2.5% Phosphate Buffered Glutaraldehyde 
1.0ml of 25% glutaraldehyde diluted in 9ml of O.lM phosphate buffer (pH 7.2). 
0.1 % Phosphate Buffered Osmium Tetroxide 
0.5ml of 2.0% osmium tetroxide diluted in 9.5ml of O.lM phosphate buffer (pH 7.2). 
2.5.2.3. Immunocytochemistry 
lQx Saline 
90g NaCl (BDH Analar) in one litre of distilled water. 
O. lM NaH2P04.2H60 
31.2g NaH2P04.2H20 (Univar) in one litre of distilled water. 
O. lM NaiHP04 
28.4g Na2HP04 (Univar) in one litre of distilled water. 
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O.OlM Phosphate Buffered Saline (PBS) 
lOOml saline (lOx) 
lOml NaH2P04.2H20 (Univar) 
lOml Na2HP04 (Univar) 
Made up to one litre with distilled water. 
4% Paraformaldehyde in PBS 
4.0g paraformaldehyde (Sigma, Cat. No. P6148) in lOOml of O.OlM PBS. 
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CHAPTER THREE 
Characterisation of Encapsulated Olfactory Ensheathing Cells 
3.1. Introduction 
Olfactory ensheathing cells are an extremely plastic cell type both in terms of their 
morphology and antigenic profile. In vitro OECs exist as flattened or spindly forms that 
closely resemble central ASTs and peripheral SCs respectively. Some authors regard 
these morphologically distinct groups as two sub-populations, those with AST-like 
properties and those with SC-like properties (Barber and Lindsay, 1982; Pixley, 1992; 
Franceschini and Barnett, 1996). Astrocyte-like OECs are identified by their flat angular 
appearance and fibrous GF AP expression while the SC-like OECs are spindly process-
bearing cells that are immunopositive for p75NTR, S-100 and diffusely positive for GFAP 
(Barber and Lindsay, 1982; Pixley, 1992; Franceschini and Barnett, 1996; Li et al., 1998; 
Sonigra et al., 1999; Alexander et al., 2002). Yet a definitive distinction between these 
two groups is difficult to make since cells with characteristics of both populations are not 
uncommon. In fact OECs have the capacity to switch between the two morphological 
profiles depending upon the composition of the media they are grown in (Pixley, 1992; 
Chuah and Teague, 1999; Vincent et al., 2003). A recent report also suggests that this 
morphological switch is regulated by cAMP and endothelin-1 (a serum component) in 
vitro (Vincent et al., 2003). Taken together these results strongly suggest that OECs 
belong to a single phenotypically plastic population rather than two distinct sub-
populations. 
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It appears that phenotypic heterogeneity is not restricted to OECs in vitro. For 
example OECs of the OB were found to differentially express Sema3A whereby only 
p75NTR positive OECs in the outer ONL not the inner ONL were Sema3A positive 
(Schwarting et al., 2000). Similarly p75NTR positive OECs were found to be restricted to 
the outer ONL, neuropeptide Y positive OECs were located in the inner ONL and GF AP 
positive OECs were restricted to the inner ONL (Au et al., 2002). Ultrastructural studies 
have also demonstrated a degree of heterogeneity in OECs in viva. Rather than being 
uniformly distributed throughout the ONL the association of OECs with axon bundles 
was orderly in the outer ONL but less so in the inner ONL. 
In recent years many studies have shown that OECs can promote the growth of 
injured axons (Ramon-Cueto et al., 1998), enhance remyelination (Franklin et al., 1996; 
Kato et al., 2000; Lakatos et al., 2003) and help restore functional connections between 
injured axons and their targets (Ramon-Cueto et al., 2000; Verdu et al., 2003). Although 
it is clear that OECs produce many neurotrophic factors (Boruch et al., 2001; Wewetzer 
et al., 2001; Woodhall et al., 2001) and cell adhesion molecules (Miragall et al., 1988; 
Pixley, 1992; Ramon-Cueto and Nieto-Sampedro, 1992; Doucette, 1996; Franceschini 
and Barnett, 1996; Kafitz and Greer, 1999; Barnett et al., 2000) that may play a role in 
their growth promoting activity there has been little progress toward our understanding of 
regenerative OEC biology. Since OECs exhibit different phenotypic characteristics 
depending upon culture conditions (Franceschini and Barnett, 1996) it is possible that the 
lesion environment induces OECs to exhibit characteristics associated with their role in 
regeneration. Similarly any changes in OEC phenotype brought about by exposure to the 
injury site could affect cell behaviour. 
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Olfactory ensheathing cells are migratory and can travel substantial distances from 
the lesion site after implantation into the injured spinal cord (Ramon-Cueto and Avila, 
1998; Ramon-Cueto et al., 1998; Ramon-Cueto et al., 2000). In these studies in vivo 
migration of OECs was examined by light microscopy of cells tagged with a fluorescent 
label. However the disadvantage of this technique is that the fluorescent label can be 
picked up by surrounding cells if the labelled cells die and/or can be diluted if the cells 
undergo proliferation (Chuah et al., 2004). OECs have been reported to enhance 
regeneration by migrating toward the injury site in vivo, suggesting that they can respond 
to signals from injured neurons (Boruch et al., 2001 ). In contrast after transection of the 
medial longitudinal fasciculus OECs were shown to migrate away from the lesion site 
and therefore failed to promote axon regeneration (Gudino-Cabrera et al., 2000). Hence 
migration could play a role in the growth promoting activity ofOECs. 
In this study OECs were immobilized within semi-permeable polymer tubes prior to 
implantation into the injured spinal cord. Since the direct cellular contacts normally 
established by implanted OECs are abolished by encapsulation this technique examines 
the potential impact of soluble factors generated by the injured spinal cord on the 
phenotypic heterogeneity of OECs. It is hypothesised that ( 1) encapsulated cells will 
adopt a different morphological phenotype in the presence of injured spinal cord tissue 
and (2) encapsulated OECs will survive in the injured spinal cord environment. 
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3.2. Materials and Methods 
3.2.1. Cell Culture 
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Olfactory ensheathing cell cultures were prepared and characterised as described in 
section 2.1.1. 
3.2.2. Preparation of OECs for Implantation 
Preliminary experiments were peformed to investigate the behaviour of OECs 
plated onto matrigel in vitro. Observations made over the course of one week showed that 
OECs differentiate and elaborate processes on matrigel in a similar way to that normally 
seen in vitro. 
Upon reaching confluency OEC cultures were encapsulated into porous polymer 
tubing prior to implantation into the injured spinal cord. Cells to be placed in capsules 
were removed from the culture flasks by trypsinisation. Flasks were rinsed with HBSS 
three times before 0.25% trypsin was added. The reaction was stopped by addition of 
MEM D-valine containing 10% dFCS. The cell suspension was then centrifuged at 500xg 
for 10 minutes. Supernatant was removed and the cell pellet containing ~2 x 105 cells 
~5µ1 was resuspended 1:1 with 5µ1 of growth factor reduced MATRIGEL ® Matrix 
(Becton Dickenson). An aliquot of suspension containing -3 x 104 cells on average was 
injected into each open-ended polymer tube (Bio/Por® Type F PVDF Hollow Fibre, 
molecular weight cut off or MWCO of 300 OOO) 6-8mm in length (Becton Dickenson). 
Tubes were heat sealed at both ends to create closed capsules. OEC-filled capsules were 
then implanted into the injured spinal cords of adult male hooded Wistar rats. Control 
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OEC-filled capsules were placed in a petri-dish containing MEM D-valine supplemented 
with 10% dFCS and incubated at 37°C for one week in a 5% C02/air incubator during 
which time three media changes were performed. 
3.2.3. Spinal Surgery 
Lesions to the corticospinal tracts (CST) of 18 adult male hooded Wistar rats (300-
350g) were performed under isoflurane anaesthesia maintained at 1.5-2.5% with 100% 
02 (flow rate of 0.5L/min). The skin overlying the spinous processes of T5-T10 was 
incised and the underlying muscles were dissected and retracted. The spinous processes 
T7 and T8 were removed along with the lamina to expose the dorsal surface of the spinal 
cord. Fine micro-dissection scissors were used to make a transverse cut across one half of 
the dorsum of the spinal cord (unilateral). After lesioning the cord a capsule containing 
OECs was placed on top of the lesion under the dura (Fig. 3.1). The overlying muscle 
was sutured and the skin closed with wound clips. After surgery animals were returned to 
their cages and kept under a heat lamp until they were fully awake. The .analgesic 
Carprofen (Pfizer) (5mg/kg) was given intraperitonealy for the following two days. One 
week after surgery rats were sacrificed by C02 inhalation and the capsules removed. 
Capsules were rinsed in O.lM phosphate buffer pH 7.2 and snap frozen in liquid nitrogen 
and stored at -80°C or processed immediately for SEM analysis. 
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FIGURE 3.1. Schematic representation of capsule placement in the lesioned rat spinal cord. 
Diagram showing a section of thoracic spinal cord with an OEC-filled capsule (grey) lying parallel 
to the length of the spinal cord above the lesion site. 
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3.2.4. Scanning Electron Microscopy 
Capsules (three implanted and three unimplanted) were fixed in 2.5% phosphate 
buffered glutaraldehyde for 20 minutes at room temperature. They were then rinsed three 
times for 5 minutes each in PBS and post-fixed in 0.1 % phosphate buffered osmium 
tetroxide (Os04) for 15 minutes at room temperature, The capsules were rinsed again in 
PBS for 3 x 5 minutes before being dehydrated in 50% and 70% ethanol for 5 minutes 
respectively. At this point the sealed ends of the capsules were removed and the 
remaining cylinder was cut in half longitudinally using the point of a 25G needle. The 
capsule halves were dehydrated through an ascending series of ethanol baths (80, 90, 95 
and 100%) 10 minutes per incubation with three incubations in 100% ethanol. They were 
then critically point dried, sputter coated with gold (Balzers) and examined using a JEOL 
JSM-840 Scanning Electron Microscope. 
3.2.6. Total Cell Number Assay 
Quantitation of total cell number in each capsule was achieved using the CytoTox 
96® Non-Radioactive Cytotoxicity Assay kit (Promega) to measure lactate 
dehydrogenase (LDH) activity. A linear standard curve was produced in which the 
absorbance generated by known numbers of free OECs was measured 
spectrophotometrically and plotted against cell number. To create the standard curve a 
dilution series of free OECs ranging from 0 - 3 x 104 cells per well (increasing in 
increments of 5000 cells) was prepared. As LDH is present in FCS the cells were 
maintained in 200µ1 of Neurobasal medium containing B-27 supplement (Life 
Technologies). Culture medium without cells was included as a background control for 
the standard curve. After overnight incubation at 37°C the cells were frozen at -80°C. 
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Eight capsules were loaded with matrigel containing 2.5 x 104 cells as described in 
section 3.2.2. As a background control some capsules were loaded with matrigel alone. 
All capsules were maintained in MEM D-valine containing 10% dFCS until the day of 
analysis when they were transferred into 200µ1 of Neurobasal (Life Technologies) 
containing B-27 supplement. The capsules (two per time-point) were analysed on day 
zero, four and seven post encapsulation, where day zero was the day the capsules were 
prepared. To analyse LDH activity cells were lysed by freeze/thaw treatment and by 
incubation with lysis buffer for 30 minutes at 37°C. Capsules were minced with vannas 
scissors to ensure that the lysis buffer could penetrate the cells. LDH activity in the 
supernatant collected from the lysed cells was performed using the assay kit described 
above, in accordance with the manufacturer's instructions. The amount of reaction 
product was measured at 492nm using a Titertek®Plus MS212 plate reader. Absorbance 
readings of the background controls were subtracted from the sample absorbance 
readings and the total cell number in each capsule was calculated using the equation (y = 
1.18341(x) + 0.2646) to the standard curve line (Fig. 3.4A). 
CHAPTER THREE: Encapsulated Olfactory Ensheathing Cell Morphology 75 
3.3. Results 
3.3.3. Morphological Changes in OECs after Implantation into the Lesioned Spinal 
Cord 
3.3.3.1. Implanted DEC-filled Capsules 
To determine if there were any morphological changes in OECs following 
implantation into the injured spinal cord OEC-filled capsules were examined using SEM 
(Fig. 3.2). Capsules were cut into halves so as the inner surfaces could be viewed 
although this released some of the contents of the capsules (Fig. 3.2A). Observations of 
the cut edge of the capsule revealed the presence of a thick extracellular matrix (ECM) 
like layer deposited on the inner surface of the capsules (Fig. 3.2B). Higher magnification 
of the capsule contents indicated the presence of small (less than 1 µm) round depositions 
or secretory droplets (Fig. 3.2C). There was also evidence of what appeared to lie clotting 
factors such as fibrin threads and red blood cells (Fig. 3.2D). No cells were seen lodged 
in the pores of the capsules. A number of larger cells with a rounded morphology were 
also observed. These were presumed to be OECs - despite their uncharacteristic 
morphology - on the basis of their size (-lOµm) and the similarity between these cells 
and some of their in vitro counterparts (Fig. 3.2E and F).In some cases the rounded cells 
were surrounded and therefore obscured by the heavy ECM making it difficult to 
examine their morphology. 
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3.3.3.2. DEC-filled Capsules In Vitro 
In contrast to the implanted capsules the inner surface of the capsules maintained in 
vitro appeared to be devoid of cells (Fig. 3.3A). Similarly the cut edge of the control 
capsules lacked the abundant ECM observed in the implanted capsules (Fig. 3.3B). Close 
inspection of the inner surface of the cultured capsules revealed the presence of a small 
number of cells with characteristic OEC-like morphology (Fig. 3.3C, D, E and F).These 
cells were -1 Oµm in diameter and were flattened bipolar or multi polar in shape. However 
there were also some rounded cells (as described in section 3 .3 .3 .1 ), secretory depositions 
(Fig. 3.3D, E and F) and a small amount of ECM (Fig. 3.3E and F).In comparison to the 
implanted capsules there appeared to be fewer cells. 
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FIGURE 3.2. Scanning electron micrographs of implanted encapsulated olfactory ensheathing cells 
(OECs). 
Encapsulated OECs were implanted into the injured rat spinal cord for one week. (A) Capsules were 
removed from the animals, cut into halves and examined by scanning electron microscopy. (B) The cut 
edge showed a thick layer of extracellular matrix deposited on the inner surface of the capsule. (C) Higher 
magnification of the capsule contents showed evidence of secretory droplets (black arrow) and fibrin 
threads (white arrow). (D) Red blood cells were also present. (E) OECs with rounded morphology were 
frequently surrounded by (F) fibrin threads (white arrow) and secretory depositions (black arrow). 
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FIGURE 3.3. Scanning electron micrographs of cultured encapsulated olfactory ensheathing cells 
(OECs). 
Encapsulated OECs were maintained in MEM D-valine with I 0% FCS at 37°C, 5% C02 for one 
week. (A) Capsules were cut into halves and examined by scanning electron microscopy. (B) The cut edge 
of the capsule showed a lack of robust extracellular matrix deposition. (C, D) High magnification of the 
inner capsule surface showed evidence ofOECs with tissue culture-like morphology (arrows), (E) secretory 
droplets (arrows) and a small amount of (F) extracellular matrix (arrows). 
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3.3.5. OEC Survival after Encapsulation 
To determine if encapsulation affected the viability of OECs the total number of 
viable cells present per capsule was measured over time. In this assay cell number was 
determined at day zero (or the point of encapsulation), then at four and seven days in 
vitro. On day zero 1.14 x 104 ± 3.15 x 102 cells were present in the capsules. After four 
days within the capsules 41 % of these cells remained viable (ie. 4. 71 x 103 ± 1.27 x 102 
cells) (Fig. 3.4B). At day seven the decline in cell number had ceased and the population 
remained stable (ie. 4.97 x 103 ± 1.67 x 102 cells remaining). 
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FIGURE 3.4. The effect of encapsulation on olfactory ensheathing cell (OEC) survival over time in 
culture. 
OEC survival was determined by measuring the total viable cell number at the time of encapsulation 
(day zero) and then after four and seven days in culture at 37°C, 5% C02 in serum-free medium. (A) The 
standard curve from which the total viable cell number was extrapolated for each time-point. (B) Graph 
showing the number of viable cells per capsule over time in culture. 
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3.4. Discussion 
This study investigated the response of OECs to soluble factors present within the 
injured spinal cord. The results of this report suggest that OEC morphology may change 
after implantation into the injured spinal cord with respect to that seen in vitro. After 
implantation most encapsulated OECs displayed what appeared to be a rounded 
morphology and produced abundant ECM. A small number of cells with tissue culture-
like morphology may also have been present. In fact such cells would have been attached 
to the inner surface of the capsules and were potentially obscured by the ECM. Similarly 
the rounded cells may also have had processes that were obscured by debris. 
In contrast, a majority of encapsulated OECs maintained in vitro displayed a bipolar 
or multipolar morphology and secreted moderate amounts of ECM. Yet there were also a 
small number of rounded cells in the in vitro capsules similar to those seen after 
implantation. It was also noteworthy that very few cells remained adherent to the walls of 
capsules maintained in vitro. The low numbers of cells combined with the fact that large 
cell clusters were seen floating in solution after the capsules were dissected for 
processing could indicate that they were loosely attached to the capsule due to a lack of 
ECM to bind them. 
It was also notable that the debris within the implanted OEC-filled capsules 
contained red blood cells although white blood cells and other inflammatory cells may 
have been present but not identified. A possible explanation for this could be that the 
cells migrated through the pores in the polymer capsule. But the fact that no cells were 
seen lodged in the pores of the capsules could indicate that only a limited number of cells 
migrated in. 
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To determine whether cells from the spinal cord were migrating into the capsules 
real-time RT-PCR for the housekeeping gene GAPDH was performed on three empty 
capsules that were implanted into the injured spinal cord. Approximately 200pg of 
GAPDH was detected per capsule on average. Since an average of -4000pg of GAPDH 
was detected per implanted OEC-filled capsule contaminating cells could have 
contributed to -5% of the total GAPDH levels in the implanted OEC-filled capsules. 
Therefore the fact that only a small amount of GAPDH mRNA was detected supports the 
notion that only a small number of cells migrated into the capsules. In addition when 
OEC-filled· capsules were· maintained in vitro no cells were found to migrate out of the 
capsules into the culture dish. Therefore any loss of OECs from the capsules may be 
more likely to have occurred during processing as described earlier. 
Since it was difficult to positively identify OECs in the implanted capsules by SEM 
alone attempts were made to pre-label the cells with Hoescht dye prior to encapsulation 
and to immunostain for specific antigens after implantation. However these techniques 
were unsuccessful mainly due to the difficulties experienced in sectioning the capsules 
for microscopy. More specifically the capsule polymer was difficult to cut using 
conventional techniques and the cells inside the capsules were not attached to the 
polymer firmly enough to withstand the rigors of processing. If sectioning were possible 
OECs could have been identified by immunostaining for p75NTR, GFAP and S-100 or by 
pre-labeling as mentioned. The fact that the antigenic profile of OECs is variable suggests 
that a battery of antigens may be required. Furthermore it would also have been possible 
to confirm the presence or absence of contaminating cells such as lymphocytes, 
macrophages and fibroblasts by immunostaining for specific antigens such as CD3 on T-
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lymphocytes, CD21 on B-lymphocytes, ED-I on macrophages and Thy I.I on 
fibroblasts. 
If in fact injury-associated soluble factors in the spinal cord do induce 
morphological change in OECs the mechanism for this change is unclear. However a 
recent study proposed that morphological plasticity in OECs is regulated by a RhoA 
dependent mechanism (Vincent et al., 2003). The authors theorise that the RhoA 
signalling cascade regulates organization of the actin cytoskeleton in OECs in a similar 
manner to that described for ASTs (Suidan et al., 1997; Safavi-Abbasi et al., 2001). By 
analogy it is possible that factors intrinsic to the CNS injury environment trigger RhoA 
and induce morphological plasticity in implanted OECs. Since the CNS lesion 
environment is extremely complex there could be an array of inflammatory molecules 
that influence the state of RhoA and therefore affect OEC morphology (see review by 
Baeryre and Schwab, 2003). 
The cell survival assay revealed that the number of viable encapsulated OECs 
declined between initial encapsulation and four days in vitro after which the population 
number remained stable but did not increase. The decline in cell number could either 
represent cell death or a transition by these cells into a state of senescence or "arrested" 
proliferation. A clearer picture may be obtained by performing the same experiment with 
an equal number of free OECs for comparison with the encapsulated cells. If the 
population number of free OECs declined at the same rate as the encapsulated cells it 
could suggest that encapsulation does not affect survival/proliferation, whilst a less rapid 
decline in free OECs may indicate that encapsulation has a direct effect on cell 
survival/proliferation. However the effect of cell density per capsule on cell survival was 
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not investigated. It is possible that a higher density of OECs per capsule could improve 
survival rate since OECs produce growth/survival factors that act in an autocrine manner 
(Chuah and Teague, 1999; Chuah et al., 2000; Woodhall et al., 2001). 
The proliferative state of encapsulated OECs compared with free OECs could be 
investigated further by western blot analsysis of cell cycle proteins involved in growth 
arrest. In a previous study it was found that astrocyte conditioned medium (ACM) 
although moderately mitogenic for OECs blocks their long-term proliferation (Alexander 
et al., 2002). This growth arrest response was accompanied by an upregulation of the 
cyclin dependent kinase inhibitors p 16 and p27 known to be involved in tri.ggering 
growth arrest in rodent cells (Alexander et al., 2002). Similarly switching OECs from 
ACM into serum- or growth factor-supplemented medium not only reversed proliferation 
arrest but also downregulated p16 and p27 expression. In light of their role in OEC 
proliferation in vitro these and other cell cycle proteins could potentially be involved in 
the cessation of growth in encapsulated OECs. 
If encapsulation decreases OEC viability and/or proliferation these cells could 
benefit from the addition of mitogens and survival factors prior to implantation into the 
injured spinal cord. Candidate molecules for this application could include, members of 
the neuregulin family such as heregulin (HRG) and glial growth factor (GGF) or 
fibroblast growth factor 2 (FGF-2), platelet derived growth factor (PDGF), insulin-like 
growth factor 1 (IGF-1) and forskolin (FSK) which ":'hen used alone or in combination 
can enhance proliferation and survival of OECs in vitro (Chuah and Teague, 1999; 
Pollock et al., 1999; Chuah et al., 2000; Yan et al., 2001b; Alexander et al., 2002). In fact 
a previous study showed that growth arrested OECs could proliferate after addition of 
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FSKIFGF-2, FSK/HRG-~1, FSK/GGF-2 and HRG-~1/FGF-2 diluted m ACM 
(Alexander et al., 2002). 
Although this study used a single technique to examine OEC morphology in the 
CNS injury environment the preliminary results are promising. The major limitation 
imposed by the use of SEM in this instance is that it cannot definitively characterise cell 
types. Hence the identity of OECs is based solely on their distinct morphological 
characteristics, which were sometimes difficult to define due to the heavy ECM deposits. 
This was further hampered by the fact that contaminating cells such as red blood cells 
were found within the capsules and the presence of others cannot be ruled out. Given this 
further investigation will be necessary to characterise the OECs, determine the identity of 
contaminating cells and to confirm the morphological changes observed. 
Immunohistochemistry for antigens such as p75NTR, GFAP, N-CAM and S-100 could 
help to characterise the OECs. Similarly contaminating inflammatory cells such as B and 
T lymphocytes could be identified by immunostaining for specific antigens. Transmission 
electron microscopy (TEM) on pre-labelled capsule sections could also be used to gain a 
clearer picture of OEC morphology especially if sections could be cut on different planes. 
Nevertheless the data presented in this study provide preliminary evidence 
indicating that morphological plasticity in OECs is facilitated by soluble factors within 
the injured spinal cord. The effect of morphological change on OEC function and what 
role it plays in the capacity of OECs to promote repair of the injured spinal cord is 
unknown. However it has been suggested that morphological plasticity in OECs may be 
an important factor in their ability to support the ongoing growth of olfactory axons and 
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that this could underlie their ability to initiate repair in the injured CNS (Van Den Pol, 
2003). 
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CHAPTER FOUR 
Optical PCR for N euregulins in Olfactory Ensheathing Cells 
4.1. Introduction 
The neuregulins are a family of proteins initially discovered due to their 
involvement in neural and cardiac development (Meyer et al., 1997). There are four genes 
known to encode the neuregulins termed nrg-1, nrg-2, nrg-3 and nrg-4 (Orr-Urtreger et 
al., 1993; Carraway et al., 1997; Chang et al., 1997; Zhang et al., 1997; Harari et al., 
1999). The nrg-1 gene is well characterised and gives rise to multiple variants, classified 
as Type-I or NDF/HRG or ARIA, Type-II or GGF and Type-III or SMDF on the basis of 
their specific N-termini (Meyer et al., 1997). Diversity among products of this gene arises 
by the use of different promoters and alternative splicing. In general nrg-1 products are 
synthesised by splicing together different combinations of the same structural domains. 
These domains include an amino-terminus, an immunoglobulin-like domain, a 
glycosylation rich spacer, an EGF-like domain, a juxtamembrane domain, a 
transmembrane domain and a cytoplasmic domain (Wen et al., 1992). The EGF domain is 
common among all nrg-1 products and can be alternatively spliced to produce a- and~­
variants. This domain is also thought to be responsible for receptor activation (Wen et al., 
1994). 
Nrg-1 isoforms influence many aspects of glial cell function including proliferation, 
differentiation and survival in SCs (Dong et al., 1995; Grinspan et al., 1996) OLGs 
(Canoll et al., 1996; Raabe, 1997; Vartanian et al., 1997), ASTs (Pinkas-Kramarski et al., 
1994; Francis et al., 1999) and OECs (Pollock et al., 1999; Chuah et al., 2000; Yan et al., 
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2001b; Alexander et al., 2002). Nrg-1 isoforms are also produced and secreted by glial 
cells such as SCs (Raabe et al., 1996; Rosenbaum et al., 1997; Cheng et al., 1998), ASTs 
(Pinkas-Kramarski et al., 1994; Francis et al., 1999), OLGs (Raabe, 1997; Raabe et al., 
1998) and OECs (Boruch et al., 2001). Moreover AST-derived nrg-1 isoforms act as 
mitogens and survival factors for OECs in vitro (Pollock et al., 1999; Alexander et al., 
2002). 
Nrg-1 products bind to and activate members of the class I EGF receptor tyrosine 
kinase family, erbB2, erbB3 and erbB4. The different homo- and hetero-dimeric 
combinations of these receptors can elicit different cellular responses depending upon the 
isoform and cellular context (Riese et al., 1995; Pinkas-Kramarski et al., 1996; Sweeney 
et al., 2000). Glial cells such as SCs, OLGs (Vartanian et al., 1997), ASTs (Francis et al., 
1999) and OECs (Pollock et al., 1999) are known to express members of the erbB 
receptor family. This suggests that these cell types not only respond to axonal-derived 
nrg-1 signals but may also use nrg-1 in an autocrine manner as has been shown for SCs 
(Rosenbaum et al., 1997). 
It is well documented that OECs support axonal outgrowth throughout life 
(Doucette, 1990; Farbman, 1990) and that implantation of these cells into the injured 
spinal cord enhances outgrowth of injured axons and promotes functional recovery 
(Ramon-Cueto and Nieto-Sampedro, 1994; Li et al., 1998; Ramon-Cueto et al., 1998). 
Yet the properties of OECs after they are transplanted into injured spinal cord remain to 
be investigated. As OECs in vitro are known to be extremely heterogeneous in terms of 
both morphology and antigenic profile (Barber and Lindsay, 1982; Pixley, 1992; Ramon-
Cueto and Nieto-Sampedro, 1992; Barnett et al., 1993; Franceschini and Barnett, 1996; 
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Vincent et al., 2003) it is possible that they may undergo a shift to a regeneration 
promoting phenotype when exposed to the injury environment. 
In this study the nrg-1 gene was chosen as a candidate for analysis of the potential 
variation in OEC phenotype after implantation into the injured CNS for several reasons. 
First, specific isoforms of nrg-1 act as mitogens and survival factors for OECs in vitro 
(Pollock et al., 1999; Alexander et al., 2002). Second, it has been suggested that nrg-1 
expression may promote olfactory axon outgrowth after injury (Salehi-Ashtiani and 
Farbman, 1996; Thompson et al., 2000; Williams et al., 2004). Third, preliminary RT-
PCR analysis- has demonstrated that cultured OECs express an array of nrg-1 isoforms 
(Thompson et al., 2000). Fourth, changes in nrg-1 expression in OECs have been 
observed after olfactory nerve injury (Thompson et al., 2000). Given these observations it 
is concievable that contact with soluble factors in the CNS injury environment may 
induce changes in nrg-1 expression in OECs and that such changes could be associated 
with their growth promoting behaviour. Especially since expression of nrg-1 and its 
receptors are known to be crucial for nervous system development (Kramer et, al.,. 1996; 
Erickson et al., 1997; Meyer et al., 1997; Britsch et al., 1998) and potentially for 
regeneration. Therefore the focus of this study was to confirm the normal expression 
pattern of nrg-1 in OECs in vivo compared with other cell types and to quantitatively 
examine whether exposure to soluble factors in the injured spinal cord affects nrg-1 
expression in encapsulated OECs. The results of this study will then provide a starting 
point for future analyses of the growth promoting properties of OECs at the injury site. 
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4.2. Materials and Methods 
4.2.1. Cell Culture and Tissue Collection 
Olfactory ensheathing cells, ASTs and fibroblasts (FBs) were cultured and 
characterised according to the methods described in sections 2.1.1. to 2.1.3. Olfactory 
ensheathing cells were encapsulated into polymer tubing and implanted into the lesioned 
spinal cord as described in the previous chapter. Neonatal rat brain tissue was collected as 
described in section 2.3. 
4.2.2. Total RNA isolation and Quantitation 
Total RNA was isolated from all cells and tissues using Trizol Reagent (Life 
Technologies) as described in section 2.4. Quantitation was performed as described in 
section 2.4.1. 
4.2.3. Principle of TaqMan Real-Time PCR 
During conventional PCR a DNA sample is heated to separate its complementary 
strands (denatured). Subsequent cooling allows specific primers added to the reaction mix 
to hybridise to their complementary target sequence in the DNA sample. Heat stable Taq 
polymerase then catalyses the synthesis of a new complementary DNA strand. During 
each cycle the amount of target DNA synthesised is doubled. The amplified target can 
then be separated on the basis of size by agarose gel electrophoresis and visualised by 
ethidium bromide staining. 
Real-time (or optical) PCR is performed in a similar manner to conventional PCR. 
In addition to specific primers and Taq polymerase a flurogenic probe is added to the 
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reaction mix. These probes, referred to as TaqMan probes, are short strands of DNA 
whose sequence is complementary to that of the DNA target. The probes are dual-
labelled with reporter and quencher dyes which are attached to the 5' and 3'ends 
respectively (Fig. 4.1). In the intact probe the close proximity of the quencher blocks (or 
quenches) the fluorescence of the reporter dye (by Forster Resonance Energy Transfer, or 
FRET). During each PCR cycle Taq polymerase cleaves the probe molecules from the 
target DNA allowing primer extension to continue to the end of the target DNA strand 
due to its exonuclease activity (Fig. 4.1). Cleavage also separates the reporter from the 
quencher dye thereby increasing the reporter dye signal. With each cycle more reporter 
dye molecules are cleaved from their respective probes increasing the flµorescence 
intensity in proportion to the amount of product generated. 
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FIGURE 4.1. Schematic diagram showing the TaqMan® RT-PCR mechanism. 
Two fluorescent dyes, a reporter (R) and a quencher (Q) are attached to the 5' and 3' ends of the 
TaqMan® probe respectively. When both dyes are attached to the probe reporter dye fluorescence is 
quenched. During the extension phase of each PCR cycle Taq polymerase displaces the probe allowing 
extension to continue to the end of the target DNA strand. This process also cleaves the reporter dye from 
the probe. Once the reporter and quencher dyes are spatially separated the fluorescence intensity of the 
reporter dye increases. With each PCR cycle the intensity of reporter dye fluorescence increases 
proportionally to the amount of specific product generated. 
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4.2.4. TaqMan Probe and Primer Design 
TaqMan quantitative RT-PCR probes and primers were designed to selectively 
detect different subtypes of rat Nrg-1 transcripts, as defined by (Marchionni et al., 1993). 
It has been previously demonstrated that the domain structure observed in different 
variants encoded by the human nrg-1 gene is generated by alternate splicing of genomic 
exons. These variants can be classified into several subtypes (NDFIHRG, SMDF, GGF 
and ARIA), based on the presence or absence of the alternately spliced exons. 
Since the genomic structure of the rat nrg-1 gene is currently unknown, a strategy 
was devised to delineate the exon-exon boundaries (and hence, domain boundaries) of rat 
nrg-1 by comparison of all known rat Nrg-1 cDNAs against the human genomic nrg-1 
sequence. Thus, all known rat nrg-1 cDNA sequences from GenBank were aligned with 
the complete human gene sequence and putative exon-exon boundaries within the cDNAs 
were defined. These boundaries were consistent for all cDNAs examined (10), indicating 
that this approach is robust. Identification of exon-exon boundaries allowed design of 
RT-PCR primers (six forward, six reverse) targeted to specific rat nrg-1 exons (Table 4.1 
and Fig. 4.2): Further specificity was given by design of three TaqMan probes, which 
specifically hybridised to the immunoglobulin domain common to NDF and GGF (probe 
1; exon 3), EGF common domain (probe 2; exon 6) and to a separate region of the EGF 
common domain (probe 3; exon 6) (Fig. 4.2). In appropriate combinations as outlined in 
Table 4.2, it was possible to perform PCR specific for up to nine subtypes of rat nrg-1. 
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A probe and primer set for GAPDH was designed to amplify the region 
corresponding to nucleotides 1603-1669 of GenBank sequence accession number 
AF 106860 producing a product with an expected size of 67bp. The probe sequence was 
located between nucleotides 1630-1647 of AF106860. 
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FIGURE 4.2. Putative representation of the rat neuregulin-1 (nrg-1) gene including the locations of 
all primers and probes. 
(A) The putative arrangement of exons includes, SMDF, GGF, NDF, immunoglobulin (Jg), glycoplasmic 
(Glyco), EGF, alpha (a), beta (b), juxtamembrane (JM), transmembrane (TM) and cytoplasmic. Right 
facing arrows represent forward primers including Nrg-Fl , Nrg-F2, Nrg-F3, Nrg-F4, Nrg-F5, Nrg-F6. Left 
facing arrows represent reverse primers as follows, Nrg-RI , Nrg-R3 , •-R , Nrg-R5 , Nrg-R7, >-RS. 
Lines represent probes, including Nrg-PI , Nrg-P2, Nrg-P3 . (B) Shows one of the many possible cDNA 
isoforms for each major Nrg-1 subtype. The primer combinations shown are specific for each subtype 
although more than one isoform of each could be amplified using these primer sets. 
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TABLE 4.1. TaqMan® probe and primer sequences the neuregulin-1 (nrg-1) gene. 
Probes and Primers 
Forward Primers 
Nrg-Fl 
Nrg-F2 
Nrg-F3 
Nrg-F4 
Nrg-F5 
Nrg-F6 
Reverse Primers 
Probes 
Nrg-Rl 
Nrg-R3 
Nrg-R4 
Nrg-R5 
Nrg-R7 
Nrg-R8 
Nrg-Pl 
Nrg-P2 
Nrg-P3 
Sequences 5' - 3' 
GAGGTCAGCCGGGTGTTGT 
CGAGGGCGACCCGAG 
GTGAGAACACCCAAGTCAGGAAC 
TTCTTCATCCACATCAACATCCA 
TGCCTCCCAGATTGAAAGAAA 
GCGAGTGCTTCACGGTGAA 
TTTCGCACCGGAGCACTAG 
CCCCCATTCACACAGAAAGTTT 
GCATGCTCCTACTCAGGCAGA 
TCTTCTGGTAGAGTTCCTCCGCT 
TTGTCAGCACCCTCTTCTGGT 
TCCAGTGAATCCAGGTTGGC 
CCAGGAGTCAGCTGCAGGCTCCAA 
TGGGACCAGCCATCTCATAAAGTGTGC 
CCTGTCAAACCCGTCAAGATACTTGTGCAA 
Probe and primer sequences were designed using primer express 1.0. 
96 
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TABLE 4.2. Specific probe/primer combinations for the neuregulin-1 (nrg-1) subtypes. 
Target Exons Target Length 
Probe 1 
Nrg-Fl Nrg-Rl GGF 1+3 106 
Nrg-F2 Nrg-Rl NDF 2+3 95 
Nrg-F5 Nrg-Rl NDF/GGF (lg domain) 3 72 
Probe 2 
Nrg-F4 Nrg-R3 EGFdomain 6 87 
Nrg-F4 Nrg-R4 Secreted 6+7/8+10 240 
Nrg-F4 Nrg-R5 Transmembrane 6+8+9+11 221 
Nrg-F3 Nrg-R3 SMDF 0+6 149 
Probe3 
Nrg-F6 Nrg-R7 ~-types 6+8 147 
Nrg-F6 Nrg-R8 a-types 6+7 174 
1 Nrg-1 transcript classes were identified by combining each specific probe with the forward (Nrg-F) and 
reverse primer (Nrg-R) combinations shown above. 
2 Amplicon length is given in base pairs. 
3 Target exons of the nrg-1 gene amplified by each primer set are shown. 
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4.2.5. RT-PCR Procedure 
RT-PCR was performed using the one-step TaqMan®.EZ RT-PCR Kit (Applied 
Biosystems, Cat. No. N808-0235) according to the manufacturer's protocol. 
Amplification reactions were performed in a final volume of 25 µl containing -50ng total 
RNA sample, 2-4mM MnOAc (depending on the isoform), 0.3mM dATP, dCTP, and 
dGTP, 0.6mM dUTP, O.lOU/µl rTth DNA polymerase and O.OlU/µl AmpErase UNG in 
Ix RT-PCR buffer. The final concentration of GAPDH forward and reverse primers was 
500nM whilst the probe concentration was 250nM. The final concentration of the nrg 
primers was 900nM and the probes were 250nM. The concentration of each mRNA 
isoform was measured using the Rotorgene 2000 thermal cycler (Corbett Research). 
Amplification conditions included 2 minutes at 50°C, 30 minutes at 60°C, 5 minutes at 
95°C and then run for 45 cycles at 94°C for 15 seconds and 60°C for 1- minute. Products 
were separated according to size by agarose gel electrophoresis on a 1.5% gel. Separated 
products were then stained with ethidium bromide and visualised under UV light to 
ensure they were the correct size (not shown). 
4.2.6. Data Analysis (Relative Quantitation) 
Relative quantitation is a method whereby a gene of interest (e.g. nrg-1) is 
compared to a housekeeping gene (e.g. GAPDH) in a test sample with the result being a 
ratio (Fig. 4.3). In real-time relative RT-PCR a standard curve is generated from a 
dilution series using a reference RNA sample. The reference sample used in this study 
was neonatal rat brain RNA (which is known to express each nrg-1 subtype). To generate 
the standard curves five different concentrations of neonatal rat brain RNA (e.g. 200, 20, 
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2.0, 0.2 and 0.02ng) were prepared. The units (ng or pg etc.) used to describe the dilution 
series were relative based on the dilution factor of the standard curve. Standard curves 
were generated for each nrg-1 subtype and GAPDH so as to compensate for their 
different amplification efficiencies. Test samples were always analysed at the same time 
as the standard curves to eliminate interference caused by run-run variations. The 
concentrations of each nrg-1 subtype and GAPDH in the test samples (e.g. OEC and 
ASTs) were then calculated by extrapolation of CT values from the line of best fit on the 
corresponding standard curve (see Fig 4.1 and example calculation p. 101). CT values are 
defined as the cycle number at which the sample fluorescence signal passes a fixed 
threshold above baseline. The concentration of the nrg-1 subtypes in each sample were 
then normalised to GAPDH by dividing each value by the corresponding GAPDH value. 
The results for each test sample were then averaged (see example Table 4.3). The 
statistical significance (student's t-test) was also calculated where appropriate. Data were 
considered statistically significant if the p value was less than 0.05. For each 
experimental sample target expression level was determined by dividing the normalised 
quantity of the specific target by the normalised quantity of that target in a calibrator 
sample. Thus the calibrator sample becomes the 1 x sample and all other quantities are 
expressed as an n-fold difference relative to the calibrator. For example an appropriate 
calibrator sample for implanted encapsulated OECs would be unimplanted encapsulated 
OECs. 
CHAPTER FOUR: Neuregulin in Olfactory Ensheathing Cells 100 
Relative quantitation method 
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FIGURE 4.3. Flow chart showing an overview of the relative quantitation method. 
For each test sample a standard curve for all Nrg-1 subtypes and GAPDH were generated using rat brain 
RNA as a reference sample. The test samples were run at the same time as the corresponding standard 
curves. The relative concentration ofNrg-1 subtypes and GAPDH were then calculated for the test samples 
by inserting the specific Cr values into the line of best fit equation for the corresponding standard curve. 
Values for each Nrg-1 subtype in all test samples were normalized to GAPDH by dividing the Nrg-1 values 
by the corresponding GAPDH values. 
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30 35 40 
30 35 40 
R = 0.99872 
log Cone= -0.309.CT + 11 .645 
110A5 i10A6 
Real-time quantitative RT-PCR using the TaqMan® EZ RT-PCR kit (Applied Biosytems). (A) Rat 
brain RNA was amplified at concentrations of 200ng, 20ng, 2.0ng, 0.2ng, and I~ respectively, test 
samples were run in parallel. (B) An amplification plot showing cycle number versus normalised 
fluorescence for each concentration of rat brain RNA. (C) Standard curve showing concentration versus 
threshold cycle (CT). The concentration of the mRNA transcript in the unknown samples can then be 
calculated from their specific CT values using the equation from the standard curve (calculation over page). 
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Example Calculation (using the equation to the line of best fit from a standard curve): 
•:• Log relative concentration = mCT + b 
(m =slope, CT =test sample CT value, b = y intercept) 
If the sample then has a CT value of 25 
•:• Log relative concentration (pg) = (-0.309 x 25) + 11.645 
·:· Relative concentration (pg) = 1 o<Iog relative concentration) 
•:• Relative concentration (pg) = 10<-0309 x 25> + 11 ·645 
The final concentration of specific mRNA in the test sample is 8317pg (or 8.317ng. 
It should be noted that the units for relative concentration (e.g. pg) are specified by 
the user when the standard curve is prepared and are therefore arbitrary. 
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TABLE 4.3. Calculation of normalised expression levels (NDF). 
RNA Sample Relative Concentration Relative Concentration Normalised NDF 
GAPDH(ng) NDF (ng) (NDF+GAPDH) 
OECs 
Replicate 1 35.012 157.925 4.51 
Replicate 2 37.344 180.745 4.84 
Replicate 3 39.598 181.685 4.59 
Average (NDF+GAPDH) 4.65 
ASTs 
Replicate 1 66.326 73.250 1.10 
Replicate 2 50.651 72.871 1.44 
Replicate 3 58.302 67.063 1.15 
Average (NDF+GAPDH) 1.23 
FBs 
Replicate 1 30.596 80.424 2.63 
Replicate 2 30.063 79.593 2.65 
Replicate 3 26.738 72.118 2.70 
Average (NDF+GAPDH) 2.66 
OECC 
Replicate 1 0.827 0.154 0.186 
Replicate 2 2.067 0.427 0.207 
Replicate 3 1.721 0.230 0.134 
Average (NDF~GAPDH) 0.176 
OECCI 
Replicate 1 2.286 2.684 1.16 
Replicate 2 2.123 2.692 1.27 
Replicate 3 2.113 2.321 1.10 
Average (NDF+GAPDH) 1.18 
1 Data for cultured cells is expressed as the amount of PCR product (ng) derived from a starting RNA 
quantity of 50ng per reaction. Capsule data is expressed as the amount (pg) of PCR product derived from a 
single capsule 
2 Normalised mRNA values are expressed as a ratio and are therefore unitless. 
CHAPTER FOUR: Neuregulin-1 in Olfactory Ensheathing Cells 104 
4.3. Results 
4.3.1. Quantitation of Neuregulin-1 Expression in Encapsulated Olfactory 
Ensheathing Cells 
To determine whether nrg-1 expression in OECs was affected by the in viva 
environment of the injured spinal cord quantitative RT-PCR analysis was performed on 
cells that were encapsulated and implanted (OEC Cl) into the injured spinal cord for one 
week. For comparison encapsulated cells were maintained for one week under the same 
culture conditions as the monolayered cells (OEC C). Samples were analysed in triplicate 
for each transcript and the results normalised to the houskeeping gene GAPDH (Table 
4.4). The expression level of each subtype was examined in implanted OECs relative to 
OECs in vitro (Table 4.5). After implantation of OECs into the injured spinal cord only 
NDF (p <0.001) was found to significantly increase in expression level compared with 
encapsulated OECs in vitro (Fig. 4.5A). In fact implanted OECs contained 10 ± I.3x as 
much NDF as OECs in vitro (Table 4.5). There was also an increase in expression of the 
secreted domain with 4.3 ± 2.7x as much detected in implanted compared with control 
encapsulated OECs (Fig. 4.5E and Table 4.5) yet this increase was not considered 
significant (p = 0.108) (Fig. 4.5E and Table 4.5). The expression levels ofNDF/GGF (or 
lg domain) (p = 0.026) and a-type (p = 0.007) transcripts decreased significantly after 
implantation (Fig. 4.5B and F). Only 0.07 ± 0.02x as much lg and 0.3 ± 0.1 x as much a-
type mRNA was detected in implantated OECs compared with control OECs. SMDF (p = 
0.193) and EGF (p = 0.051) transcripts also decreased in expression level, but the 
decrease was not significant (Fig. 4.5C and D). Both the transmembrane and B-type 
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isoforms were not detected in implanted encapsulated or control encapsulated OECs. No-
template controls showed no contamination with genomic DNA. 
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FIGURE 4.5. The effect of the injured rat spinal cord on neuregulin-1 (nrg-1) mRNA expression in 
olfactory ensheathing cells (OECs). 
Cultured OECs were encapsulated into porous polymer tubes and implanted into the injured rat 
spinal cord for one week (OEC Cl), or maintained in MEM D-valine supplemented with 10% dFCS at 
37°C, 5%C02 for one week (OEC C).Error bars represent standard deviation. 
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4.3.2. Comparison of Neuregulin-1 Expression in Cultured Olfactory Ensheathing 
Cells with Astrocytes and Fibroblasts 
To establish the normal nrg-1 expression profile in OECs quantitative RT-PCR was 
performed on primary cultures of OECs and compared with ASTs and FBs. Samples 
were analysed in triplicate as described above and the results normalised to GAPDH 
(Table 4.4). Expression levels in OECs were calculated relative to ASTs and FBs (Table 
4.6 and 4.7). All cell types displayed a similar pattern of expression although the levels 
varied (Fig. 4.6). All transcripts with the exception of the transmembrane variant were 
expressed in cultured OECs. Astrocytes and FBs also lacked expression of the 
transmembrane variant while FBs also lacked GGF expression (Fig. 4.6D). Olfactory 
ensheathing cells expressed higher levels of the major subtypes NDF, SMDF and GGF 
than ASTs and FBs (Fig. 4.6A, B and D, Table 4.6 and 4.7). Similarly the minor subtypes 
including, EGF, secreted, a-type and ~-type, nrg-1 were more highly expressed in OECs 
than ASTs (Fig. 4.6E, G, H and Table 4.6). One exception was the lg subtype which was 
more highly expressed in FBs than OECs (Fig. 4.6C and Table 4.6). Compared with FBs, 
OECs expressed higher levels of the minor subtypes EGF, secreted and ~-type (Table 
4.7). Unlike the other subtypes expression of a-type was highest in FBs (Fig. 4.6G and 
Table 4.7). No-template controls showed no contamination with genomic 
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FIGURE 4.6. Expression levels of neuregulin-1 (nrg-1) mRNA in primary cultures of olfactory 
ensheathing cells (OECs) astrocytes (ASTs) and fibroblasts (FBs). 
Primary cultures of OECs, ASTs and FBs were analysed for each nrg-1 mRNA subtype by real-time 
RT-PCR. Error bars represent standard deviation. 
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TABLE 4.4. Normalised expression levels of neuregulin-1 (nrg-1) mRNA in cultured and/or implanted 
encapsulated olfactory ensheathing cells (OECs), astrocytes (ASTs) and fibroblasts (FBs). 
MAJOR SUBTYPES OECC OECCI OEC AST FB 
GGF ND ND 0.008 ± 0.0002 0.004 ± 0.0001 ND 
NDF 0.123 ± 0.049 1.226 ± 0.158 4.646 ± 0.172 1.231 ± 0.182 2.658 ± 0.035 
SMDF 0.024 ± 0.009 0.016 ± 0.002 0.403 ± 0.023 0.091±0.020 0.058 ± 0.005 
MINOR SUBTYPES OECC OECCI OEC AST FB 
NDF/GGF (lg) 1.640 ± 0.768 0.108 ± 0.028 0.1442 ± 0.394 0.202 ± 0.054 0.459 ± 0.004 
EGF 0.536 ± 0.287 0.079 ± 0.013 0.946 ± 0.040 0.212 ± 0.012 0.429 ± 0.101 
Secreted 0.026 ± 0.016 0.112 ± 0.070 0.819 ± 0.327 0.162 ± 0.057 0.332 ± 0.165 
P-Types 16.160 ± .0377 4.707 ± 1.643 15.440 ± 1.609 7.423 ± 0.427 18.970±3.219 
a-Types ND ND 0.854 ± 0.278 0.057 ± 0.010 0.110 ± 0.048 
Transmembrane ND ND ND ND ND 
1 ND indicates that the isoform was not detected. 
2 Normalised mRNA levels are given in arbitrary units± standard deviation. 
3 Nrg-1 expression was compared in OEC capsules maintained in vitro (OEC C) and those implanted into 
the injured spinal cord (OEC Cl). 
CHAPTER FOUR: Neuregulin-1 in Olfactory Ensheathing Cells 110 
TABLE 4.5. Expression levels ofneuregulin-1 (nrg-1) in implanted encapsulated OECs relative to 
encapsulated OECs maintained in vitro. 
MAJOR SUBTYPES OECCI 
NDF 10 ± 1.3 
SMDF 0.7 ± 0.08 
MINOR SUBTYPES OECCI 
NDF/GGF (lg) 0.07 ± 0.02 
EGF 0.2± 0.02 
Secreted 4.3 ±2.7 
a-Type 0.3 ± 0.1 
TABLE 4.6. Expression levels ofneuregulin-1 (nrg-1) in olfactory ensheathing cells (OECs) relative to 
astrocytes. 
MAJOR SUBTYPES OEC 
GGF 2.0± 0.05 
NDF 3.8 ± 0.14 
SMDF 4.4 ± 1.15 
MINOR SUBTYPES OEC 
NDF/GGF (lg) 0.7 ± 1.9 
EGF 4.5 ±0.2 
Secreted 5.1±2.0 
a-Type 2.1±0.2 
13-Type 15.0 ± 4.9 
1Relative expression levels were calculated by dividing the normalised expression values of the test 
samples by the normalised expression values of the calibrator sample. 
2 Assuming that the calibrator has an expression value of 1 the test samples have an n-fold change in target 
expression. 
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TABLE 4.7. Expression levels ofneuregulin-1 (nrg-1) in olfactory ensheathing cells (OECs) relative to 
fibroblasts. 
MAJOR SUBTYPES 
NDF 
SMDF 
MINOR SUBTYPES 
NDF/GGF (lg) 
EGF 
Secreted 
a-Type 
P-Type 
OEC 
1.7 ± 0.1 
6.9 ± 0.4 
OEC 
0.3 ±0.9 
2.2 ± 0.1 
2.5 ± 1.0 
0.8 ± 0.1 
7.8 ±2.5 
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4.4. Discussion 
This study indicates that nrg-1 expression in OECs may be influenced by soluble 
factors within the CNS injury environment. One limitation of the real-time RT-PCR 
technique is that it relies on quantitation of nrg-1 expression normalised to the 
housekeeping gene GAPDH. Therefore the nrg-1 levels reported here are based on the 
assumption that GAPDH levels will remain constant in each cell type and in OECs 
whether implanted or not. To minimise GAPDH variation the same RNA pool was used 
for each cell type throughout the experiment, samples were not freeze-thawed multiple 
times and the same amount of RNA (ie. 50ng) was used per reaction for all cell types. To 
further improve the reliability of this technique other housekeeping genes could be used 
in addition to GAPDH or both nrg-1 and GAPDH reactions could be performed in the 
same tube (a technique known as multiplexing). However multiplex reactions require that 
the specific probes are labelled with different fluorophores whose fluorescent spectra do 
not overlap and that both primer sets use the same thermal cycling parameters. 
Another limitation of the technique used in this study is that the quantitation is 
relative therefore the reported levels are given in arbitrary units. Hence relative levels 
cannot be correlated with cell number. This problem can be overcome by performing 
absolute quantitation. Here the absolute quantity of the RNA standard must be known and 
is determined by some independent means. Usually this is achieved by measuring the 
absorbance of the RNA standard at 260nm (A260) and converting this to copy number 
using the molecular weight of the RNA. Once the absolute concentration is known the 
RNA can be used to generate the standard curve in the same manner as for the relative 
technique. Results can then be reported in absolute numbers and can therefore be related 
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to cell number. However two important factors to consider when usmg absolute 
quantitation are (1) the stability of the RNA standard and (2) the accuracy of the A260 
measurement since these are crucial for absolute quantitation. 
In this study the nrg-1 isoforms expressed by cultured OECs included NDF, SMDF, 
GGF, EGF and secreted nrg-1. Olfactory ensheathing cells expressed the highest levels of 
most subtypes relative to both ASTs and FBs. The expression profiles of ASTs and FBs 
were shown to be similar to that of OECs except that FBs lacked GGF. A similar range of 
isoforms in OECs, ASTs and SCs were reported previously (Thompson et al., 2000). 
After implantation into the injured spinal cord OECs were found to significantly increase 
expression ofNDF. A previous study showed that both NDFa and~ variants are survival 
factors for OECs, howev.er only the NDF~ variant was mitogenic (Pollock et al., 1999). 
Hence it is plausible that encapsulated OECs increase expression of NDF after 
implantation to enhance their own survival and proliferation. This seems especially likely 
given that OECs are known to express functional erbB receptors including erbB2 and 
erbB4 suggesting that they have the capacity to use these factors in an autocrine manner 
(Pollock et al., 1999). Moreover the earlier finding (see chapter three) that OEC survival 
and proliferation are potentially limited after encapsulation may lend further support to 
this possibility. 
Notably GGF expression was lacking in encapsulated OECs whether implanted or 
not. This would seem an unexpected result given that cultured OECs are known to 
express GGF (Chuah et al., 2000) and GGF transcripts were detected by real-time RT-
PCR in normal cultured OECs in this study. Since GGF is known to induce proliferation 
in OECs its absence from the encapsulated cells could be directly related to the decline in 
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cell number seen in the cultured capsules in the previous chapter. The same could also be 
true of cells in the implanted capsules assuming that a lack of GGF affected their 
proliferation in a similar manner. However, further investigation will be required to 
establish whether the lack of proliferation in encapsulated OECs is directly linked to 
GGF downregulation. 
The transmembrane nrg-1 transcript was not detected in normal cultured OECs, 
ASTs, FBs or encapsulated OECs (before or after implantation into the injured spinal 
cord). This observation did not support the findings of Thompson and colleagues (2000) 
who demonstrated the presence of the transmembrane variant in OECs. It is possible that 
this discrepancy may be related to differences in the age and strain of animals used and/or 
to the method of culture. For example cells used in this study were isolated from 2-3 day-
old Hooded Wistar rat pups and purified by serial passage and use of mitotic inhibitors to 
produce a 91 % p75NTR positive population. Cells in the previous study were prepared 
from 7 day-old Sprague-Dawley rat pups and purified by fluorescence-activated cell 
sorting (F ACS) using the 04 antigen. These factors alone may have resulted in a slightly 
different population of OECs leading to the observed discrepancy. Another possibility is 
that the use of different primer sets in each study contributed to the apparently different 
result. The transmembrane primer set used here was designed to detect a single isoform. 
However the primer set used by Thompson and colleagues was reported to amplify both 
a- and ~-transmembrane variants identified as two separate bands on the same gel. 
Furthermore they report that only the a-form is expressed by OECs, ASTs and SCs whilst 
the ~-form is expressed in the cortex (Thompson et al., 2000). This may suggest that the 
isoform detected by our primer set was the ~-form. Similarly this could explain the 
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absence of the transmembrane variant in OECs and its presence in rat whole brain total 
RNA used in this study to produce the standard curves. 
The discrepancies between this study and the previous report by Thompson and 
colleagues highlight the fact that the nrg gene is very complex. The highly alternatively 
spliced nature of nrg-1 alone combined with the fact that its exonic structure is not well 
understood indicate that further investigation of this gene may be required. 
Surprisingly little is known about how neuregulin expression is induced despite the 
fact that their bioactivity has been extensively studied. However nrg-1 expression in 
some neurons has been shown to be regulated by target interactions (Bermingham-
McDonogh et al., 1997). For example .axotomy of motor and sensory neurons reduces the 
expression of nrg-1 which is restored to normal levels after reinnervation of the target 
tissues (Bermingham-McDonogh et al., 1997). 
The functional significance associated with down-regulation of GGF particularly in 
the context of nerve repair is not known. Given that GGF promotes OEC proliferation in 
vitro, a down-regulated level of GGF could indicate that OEC growth and survival are 
compromised. However the injured spinal cord contains elevated levels of PDGF, BDNF, 
NGF, TGFJ3, FGF-2, IGF-1 and IGF-11 (Logan et al., 1992; Mocchetti et al., 1996; Lagord 
et al., 2002; Bareyre and Schwab, 2003) that could stimulate the proliferation of 
implanted OECs (Bianco et al., 2004). Future experiments could use protein arrays to 
analyse the spectrum of growth factors present in the injured spinal cord and each of the 
factors identified could then be tested for their effect on OECs in vitro. 
Neuregulin-1 proteins are necessary for the proliferation, differentiation and 
survival of OLGs the myelin forming cells of the CNS (Canon et al., 1996; Canoll et al., 
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1999; Vartanian et al., 1999; Flores et al., 2000). Hence upregulation of nrg-1 by OECs 
could promote the survival of damaged OLGs and/or the proliferation and differentiation 
of OLG precursors after CNS injury. Studies of nrg-1 knockout mice have revealed that 
the nrg-1 proteins have multiple essential roles in nervous system development, see 
review by (Falls, 2003). Hence they not only promote the survival, proliferation and 
differentiation of glial cells (Dong et al., 1995; Canoll et al., 1996; Grinspan et al., 1996; 
Raabe, 1997; Vartanian et al., 1997; Flores et al., 2000) but also promote the survival and 
migration of several neuronal populations (Anton et al., 1997; Rio et al., 1997; Britsch et 
al., 1998; Wolpowitz et al., 2000). Hence nrg-1 expressed by OECs could have an 
overall protective effect on oligodendrocytes and neurons in the injured spinal cord. 
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CHAPTER FIVE 
Nogo and Nogo-66 Receptor Expression in Olfactory 
Ensheathing Cells 
5.1. Introduction 
117 
The insulating myelin sheath produced by OLGs that surrounds axons in the CNS 
has long been associated with inhibition of axonal regeneration. Myelin gives rise to a 
number of inhibitory molecules including; MAG, CSPG, arretin and NI-35/NI-250 (or 
Nogo). Interest in Nogo initially stemmed from the finding that a monoclonal antibody 
termed IN-1 could neutralise the inhibitory effects of NI-35/NI-250 thereby enhancing 
axonal regrowth of CST fibres and promoting functional recovery when applied to a 
lesion site in viva (Schnell and Schwab, 1990; Brosamle et al., 2000). 
The Nogo gene encodes three known protein products termed Nogo-A, -B and -C, 
which are thought to arise from alternative splicing and promoter usage (Chen et al., 
2000; Oertle et al., 2003a). Nogo-A was classified as a Rtn protein, a family of ER-
associated proteins of unknown function, due to the finding that the protein is 
concentrat_ed largely in the ER with only small amounts reaching the surface of OLGs 
(GrandPre et al., 2000). This finding was thought to explain why OLGs contribute to 
axonal inhibition after injury as damaged cells could conceivably release intracellular 
stores ofNogo into the lesion environment, thereby inhibiting axonal regrowth (Goldberg 
and Barres, 2000). 
The inhibitory characteristics of Nogo were later localized to a 66 amino acid C-
terminal region referred to as Nogo-66 (found in all Nogo isoforms) and also to the N-
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terminal domain of the protein (Fournier et al., 2001). A recent study of the Nogo-A 
protein also revealed the presence of a third inhibitory domain found in the Nogo-A 
specific exon three (Oertle et al., 2003b ). The inhibitory Nogo-66 domain was found to 
interact with a GPI-linked receptor termed NgR, which is found on the axonal surfaces of 
many CNS neurons but is not expressed by OLGs. Cleavage of this receptor from the 
axonal surface renders neurons insensitive to Nogo-66 inhibition whilst induction ofNgR 
expression is sufficient to impart Nogo-66 responsiveness to previously unresponsive 
neurons (Fournier et al., 2001). This suggested that the NgR plays a major role in Nogo-
66 signaling. However because the NgR is GPI-linked to the cell surface, by analogy with 
other similarly linked proteins, it requires a transmembrane co-receptor for intracellular 
signaling. It is now known that the p75NTR can act as part of a signaling complex with 
NgR in MAG-associated neurite outgrowth inhibition (Wong et al., 2002). 
The localization ofNogo to OLGs and the NgR to the surfaces of CNS neurons fits 
well with the notion that Nogo is an inhibitor of axon outgrowth in the CNS. 
Unfortunately in the injured CNS the presence ofNogo restricts neurite regrowth thereby 
preventing regeneration. Unlike OLGs, OECs are known to be permissive to axon 
outgrowth after injury and have been shown to promote the growth of injured axons after 
implantation into the lesioned spinal cord (Doucette, 1995; Franklin et al., 1996; Ramon-
Cueto et al., 1998). In view of their growth promoting nature it would seem unlikely that 
OECs express Nogo artd its receptor ~gR. To the contrary the presence of Nogo and the 
NgR in the developing olfactory system along with the finding that p75NTR a widely 
accepted marker of OECs acts as part of a signaling complex with the NgR could suggest 
otherwise. Hence the aim of the present work was first to determine whether OECs 
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express Nogo and its receptor NgR compared with their glial counterparts It is 
hypothesised that OECs will express a low level ofNogo and its receptor NgR and that it 
will be altered when OECs are transplanted into the injured spinal cord. 
5.2. Materials and Methods 
5.2.1. Cell Cultures 
Primary cultures of OECs, ASTs and OLGs were prepared according to the 
protocols described in section 2.1.1 and 2.2.2. Purity was determined by counting cells 
labeled with the appropriate markers. Schwann cells (a gift from Adele Vincent) were 
prepared from the sciatic nerves of neonatal rats and cultured by a modification of a 
previously described protocol (Brockes et al., 1979). Schwann cells were estimated to be 
95-98% pure based on p75NTR staining. For the in vivo studies OECs were ·encapsulated 
into polymer tubes and implanted into the injured spinal cords of adult rats as described 
in sections 3.2.2. and 3.2.3. 
5.2.2. RNA Synthesis and Quantitation 
A full description of RNA synthesis and quantitation procedures can be found in 
section 2.4.1. 
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5.2.3. Principle of Real-time RT-PCR using SYBR Green 
SYBR green is a fluorescent double-stranded DNA ( dsDNA) intercalating dye (Fig. 
5.1). SYBR green is incorporated into the PCR reaction mix in addition to the regular 
reaction components (e.g. primers and Taq polymerase). SYBR green binds non-
specifically to all dsDNA and its fluorescence intensity increases when in its bound state. 
In its unbound state SYBR green emits very little fluorescence. After each amplification 
cycle the amount of dsDNA product increases and the SYBR green signal intensifies 
proportionally to the amount of product generated. 
The fact that SYBR green binds to any dsDNA can be both an advantage, or 
disadvantage. On the positive side SYBR green allows detection of any dsDNA and 
therefore be used in any amplification reaction. However the disadvantage is that both 
specific and non-specific products can generate a signal. Thus any mis-priming events or 
primer-dimer formation can generate a false positive signal. 
5.2.4. Probe and Primer Design 
To design primers for real-time RT-PCR a Genbank search was performed to locate 
all known mRNA sequences for each Nogo isoform and the NgR. The sequences were 
subjected to Blast analysis to show regions of overlap between the isoforms. A common 
primer set termed Nogo-ABC was designed to lie in the C-terminal region of the 
sequence found in all Nogo isoforms (Fig. 5.2) (Chen et al., 2000). Nogo-A primers were 
designed to lie in exon 3, a region specific to the Nogo-A isoform (Fig. 5.2). Although no 
unique sequence was found in Nogo-B, primers were designed to overlap a splice site in 
the Nogo-A sequence that produces the truncated Nogo-B sequence (Fig. 5.2). No 
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primers were designed to analyse Nogo-C as no unique regions of sequence or splice sites 
were identified. Specific NgR primers were also designed. All Nogo primer sequences 
are given in (Table 5.1). The GAPDH primers used are described in section 4.2.4. 
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FIGURE 5.1. Schematic representation of the double-stranded DNA (dsDNA) intercalating dye, 
SYBRGreen. 
Shows SYBR Green (dark blue) incorporated into a dsDNA molecule (green and blue). 
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FIGURE 5.2. Schematic diagram of the mouse nogo gene showing primer locations. 
(A) The locations of each primer set are shown as arrow heads. The Nogo-A primers are located in 
the Nogo-A specific exon 3, Nogo-B primers are located either side of the splice site that creates the 
truncated Nogo-B sequence, while the Nogo-ABC primers are located in the C-terminal region of the gene 
found in all Nogo isoforms. (B) Shows the three major isoforms ofNogo and the specific locations of the 
RT-PCR primers within each isoform. Modified from (Oertle et al., 2003a). 
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TABLE 5.1. Primer sequences for the Nogo isoforms. 
Primers 
Nogo-ABC forward 
Nogo-ABC reverse 
Noga-A forward 
Nogo-A reverse 
Nogo-B forward 
Nogo-B reverse 
NgR forward 
NgR reverse 
Sequence (5'-3') 
ATTGTAAGCTGCTGTGTATGGATCT 
ACAGCTTTCCCCGAGTCCTT 
TGTAGTGCAGCCCTTCACAG 
GCACATCCCTACTTCCCTCA 
GGCTCAGTGGTTGTTGACCT 
GGCCTTCATCTGATTTCTGG 
ACAACACCTTCCGAGACCTG 
GGCAAAACGGGTAGAGGGTCA 
1 Target length measured in base pairs. 
124 
Target Length 
89 
199 
208 
194 
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5.2.5. RT-PCR Procedure 
RT-PCR for Nogo and NgR was performed usmg the one-step QuantiTect™ 
SYBR® Green RT-PCR kit (Qiagen, Cat. No. 204243) according to the manufacturer's 
specifications. Each 25µ1 reaction contained ~50ng total RNA sample, 5mM MgCh, 1 x 
RT-PCR master mix, Ix RT mix and 500nM primers (dependant on isoform). Reverse 
transcription was performed at 50°C for 30 minutes. Amplification reactions included an 
activation step of 15 minutes at 95°C to activate the Hot Start Taq Polymerase and were 
cycled at 94°C for 15 seconds and 60°C for 30 seconds for 30 cycles on a RotorGene 
2000 thermal cycler (Corbett Research). 
5.2.6. PCR Optimisation 
Amplification of specific products and prevention of primer-dimer formation using 
SYBR green was found to be particularly dependent upon primer concentration. 
Excessive concentrations of primer inhibited the PCR amplification process and often 
resulted in a change in product melting temperature (Tm). SYBR green binds to any 
dsDNA hence the formation of primer-dimer products that occurs when excess primer 
concentrations are present can generate a signal and affect the quantitation process. 
Therefore to minimise primer-dimer formation an appropriate primer dilution series was 
used for each RNA concentration in the standard curves (for example see below). 
RNA Concentration (ng) 200 20 2.0 0.2 0.02 
Primer Concentration (nM) 500 400 300 200 100 
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5.2. 7. Data Analysis 
Relative quantitation of real-time RT-PCR data was performed as described in 
section 4.2.6. Statistical significance was determined where appropriate by student's t-
test, where a p value of less than 0.05 was considered significant. 
5.2.8. Product Characterisation 
As SYBR green binds non-specifically to dsDNA molecules melt curve analysis 
was performed to ensure that the correct mRNAs were amplified. Melt curves were used 
to determine the specific Tm of the· product and to ensure that there was little or no 
interference from primer-dimer formation. During melt curve analysis the temperature is 
raised slowly from a low temperature (ie. 65°C) to a high temperature (ie. 95°C). At low 
temperatures the RT-PCR products are double-stranded and SYBR Green binds to them 
emitting an intense fluorescent signal, hence at high temperatures RT-PCR products are 
denatured (or single-stranded) resulting in a rapid decrease in fluorescent signal. 
Fluorescence intensity is measured as the temperature increases and is plotted against 
temperature (Fig. 5.3). By plotting dF/dT of the fluorescence intensity against 
temperature a single peak is created which corresponds to the specific Tm of the product. 
The presence of other peaks would indicate the presence of non-specific products or 
primer-dimer formation. 
To verify that there was no interference from primer-dimer formation or non-
specific products all PCR products were separated on the basis of size by agarose gel 
electrophoresis on a 1.5% gel. The separated products were stained with ethidium 
bromide and visualised under UV light. The sizes of the products were determined by 
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comparing the products to a set of size standards separated on the same gel. If the product 
size correspondes to the known size, the correct product was amplified. Hence the 
presence of bands that were not the correct size could indicate the presence of non-
specific products or primer-dimers. 
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FIGURE 5.3. Melt curve analysis of the Nogo isoforms. 
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85 •c 
During melt curve analysis the fluorescence intensity of the product is measured at increasing 
temperatures. The fluorescence signal decreases dramatically at the temperature at which the product 
becomes denatured and is equivalent to the melting temperature (Tm) of that product (A). The dF/dT of 
fluorescence intensity is then plotted against temperature which shows a peak at the specific Tm of the 
product. Melt curve analysis of GAPDH 84°C, Nogo-A 81°C, h'· 85°C, Nogo-ABC 81°C, NgR 88°C. 
The no template control (NTC) (B) shows a lack of primer-dimer and non-specific product formation. 
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5.2.9. Immunocytochemical Analysis of OECs for Nogo-A and NgR 
For immunocytochemical analysis cultured OECs and OLGs were plated onto 13 
mm diameter glass coverslips at a density of 1 x 104 per coverslip. Cells were fixed with 
phosphate buffered 4% paraformaldehyde for 15 minutes at room temperature. After 
washing three times in 0.1 M phosphate buffered saline (PBS; pH 7.4) the cells were 
incubated with DAKO® protein blocking solution. The cells were incubated with 
polyclonal goat anti-Nogo-A (S-19) or Nogo (I-20) (Santa Cruz) at a final concentration 
of lOµg/ml in PBS containing 0.3% triton-X 100 for 1 hour at room temperature. The 
negative controls were incubated with PBS containing 0.3% triton-X 100 without primary 
antibody. Cells were rinsed three times and incubated with a donkey anti-goat Alexa 
Fluor 594 conjugated secondary antibody diluted 1:2000 in PBS containing triton-X 100 
for 45 minutes at room temperature. Cells were counterstained with 0.01 % Nuclear 
Yellow and mounted with DAKO® Fluorescent Mounting Medium. They were then 
examined by fluorescent microscopy using an Olympus BX50 microscope with the 
appropriate filter for the dye conjugated to the secondary antibody, The cells were 
imaged with an Olympus DP50 digital camera. 
For analysis of the NgR cultured OECs as described above were incubated with 
goat polyclonal anti-NgR (Santa Cruz) at a final concentration of lOµg/ml in PBS for 1 
hour at 37°C. Controls were incubated in PBS without primary antibody. Cells were then 
post-fixed with phosphate buffered 4% paraformaldehyde for 15 minutes at room 
temperature. After three washes in PBS cells were incubated with a donkey anti-goat 
Alexa Fluor 594 (Molecular Probes) conjugated secondary antibody diluted 1 :2000 in 
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PBS for 45 minutes at room temperature. Cells were counterstained with 0.01 % Nuclear 
Yellow. Coverslips were mounted and examined as described above. 
5.3. Results 
5.3.1. Comparison of Nogo and NgR Expression in OECs and Other Glial Cell 
Types. 
Expression of Nogo and its receptor NgR was examined by real-time RT-PCR 
analysis in cultured OECs, ASTs and SCs and normalised to GAPDH (Table 5.2). Nogo 
expression in OECs, ASTs and SCs was calculated relative to OLGs (Table 5.3). 
Oligodendrocytes were used as the calibrator cell type since they are known to express 
Nogo. Like OLGs, OECs, AST and SCs expressed Nogo mRNA (Fig. 5.4). These 
findings were in direct contrast to other reports suggesting that SCs and ASTs do not 
express Nogo (Josephson et al., 2001; Huber et al., 2002). Each cell type expressed 
Nogo-A, Nogo-B and Nogo-ABC mRNA. Unsurprisingly OECs, SCs and ASTs 
expressed 0.7 ± 0.lx, 0.5 ± O.Olx and 0.1 ± O.Olx lower levels ofNogo-A compared with 
OLGs (Fig. 5.4A and Table 5.3). Yet OECs expressed 2.9 ± 0.2x as much Nogo-B (Fig. 
5.4B) and 1.6 ± 0.5x as much Nogo-ABC (Fig. 5.4C) levels than OLGs (Table 5.3). 
Similarly SCs expressed 1.1±0.2x as much Nogo-B but less Nogo-ABC compared with 
OLGs while astrocytes expressed less Nogo-B and Nogo-ABC than OLGs (Table 5.3). 
Olfactory ensheathing cells, ASTs and SCs also expressed mRNA for the NgR (Fig. 
5.4D), which was not detected in OLGs. This observation confirmed previous reports 
suggesting that OLGs lack the NgR (Josephson et al., 2002). 
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FIGURE 5.4. Nogo and NgR mRNA expression in primary cultures of olfactory ensheathing cells 
(OECs) and other glial cell types. 
Primary cultures of OECs, ASTs, SCs and OLGs. Levels of Nogo-A (A), Nogo-B (B) Nogo-ABC 
(C) and NgR (D) were examined in each cell type by real-time RT-PCR using SYBR green. Error bars 
represent standard deviation. 
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5.3.2. Quantitation of Nogo Expression after Implantation into the Injured Spinal 
Cord. 
To determine if Nogo expression in OECs was affected by implantation into the 
injured spinal cord OECs were encapsulated and maintained in vitro (OEC C) or 
implanted into the lesioned spinal cord for one week (OEC Cl) (Table 5.2). Expression 
levels for implanted OECs were calculated relative to in vitro OECs (Table 5.4). After 
encapsulation OECs retained expression of Nogo-A, Nogo-B and Nogo-ABC mRNAs 
(Fig. 5.5). However implantation resulted in a significant increase in the expression level 
of Nogo-A (2.8 ± 0.7x) (p = 0.012) (Fig. 5.5A) and Nogo-B (p <0.001) (17.1 ± 2.9x) 
(Figure 5.5B and Table 5.4)) and a significant decrease in Nogo-ABC (p = 0.039) (0.2 ± 
O.lx) (Fig. 5.5C and Table 5.4) compared with encapsulated cells maintained in vitro. 
Unlike normal cultured OECs, encapsulated OECs lacked NgR expression, which 
remained unchanged after implantation into the injured spinal cord. 
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FIGURE 5.5. The effect of the injured rat spinal cord on Nogo mRNA expression in encapsulated 
olfactory ensheathing cells (OECs). 
Encapsulated OECs were analysed for Nogo-A (A), Nogo-B (B), Nogo-ABC and NgR (C) by real-
time RT-PCR after implantation into the spinal cord for one week (OEC Cl). As a comparison un-
implanted encapsulated OECs were analysed after one week in MEM D-valine supplemented with 10% 
dFCS at 37°C, 5%C02 (OEC C).Error bars represent standard deviation. 
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TABLE 5.2. Normalised expression levels ofNogo and NgR in encapsulated and/or cultured olfactory 
ensheathing cells (OECs), astrocytes (ASTs) and Schwann cells (SCs). 
TARGET OEC C OEC Cl OEC OLG SC AST 
Nogo-A 0.015 ± 0.002 0.042 ± 0.010 0.303 ± 0.044 0.409 ± 0.070 0.218 ± 0.006 0.054 ± 0.004 
Nogo-B 0.130±0.041 2.219±0.382 14.04±1.018 4.79±0.379 5.41±0.875 2.74±0.100 
Nogo-ABC 5.016 ± 2.040 1.355 ± 0.496 0.633 ± 0.180 0.394 ± 0.207 0.325 ± 0.022 0.091 ± 0.011 
NgR ND ND 0.116 ± 0.019 ND 0.023 ± 0.002 0.017 ± 0.003 
1 The presence ofND indicates that the isoform was not detected. 
2 Normalised rnRNA levels are given in arbitrary units± standard deviation. 
3 Encapsulated OECs maintained in vitro (OEC C) were compared with encapsulated cells implanted into 
the injured spinal cord (OEC Cl). 
TABLE 5.3. Expression levels of Nogo in olfactory ensheathing cells (OECs), astrocytes (ASTs) and 
Schwann cells (SCs) relative to oligodendrocytes (OLGs). 
TARGET OEC SC AST 
Nogo-A· 0.7 ± 0.1 0.5 ± 0.01 0.1±0.01 
Nogo-B 2.9±0.2 1.1±0.2 0.6 ± 0.02 
Nogo-ABC 1.6 ± 0.5 0.8 ± 0.06 0.2± 0.03 
TABLE 5.4. Expression levels of Nogo in implanted encapsulated OECs (OEC Cl) relative to 
encapsulated OECs maintained in vitro. 
TARGET OECCI 
Nogo-A 2.8 ±0.7 
Nogo-B 17.l ± 2.9 
Nogo-ABC 0.2 ± 0.1 
1Relative expression levels were calculated by dividing the normalised expression values of the test 
samples by the normalised expression values of the calibrator sample. 
2 Assuming that the calibrator has an expression value of 1 the test samples have an n-fold change (see 
above) in target expression. 
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5.3.3. Cultured OECs Express Nogo-A Protein 
RT-PCR analysis demonstrated that cultured OECs, regardless of whether they are 
encapsulated and implanted in the spinal cord or not, consistently express Nogo (Table 
5.2). In contrast, NgR mRNA was only present in unencapsulated OECs (Fig. 5.4). 
lmmunocytochemical analysis of cultured OECs from flasks revealed that the cells were 
positive for Nogo-A (Fig. 5.6) and negative for NgR. Similarly cultured OLGs were 
immunopositive for Nogo-A (Fig. 5.6) and negative for NgR. Interestingly Nogo-A in 
cultured OECs could only be detected after the cells were permeabilised, suggesting that 
Nogo-A was intracellular (Fig. 5.7). However in OLGs Nogo-A was detected with or 
without permeabilising the cells, indicating that the protein was probably both intra- and 
extracellular. This finding confirms previous reports suggesting that Nogo-A protein is 
largely intracellular in OLGs with small amounts reaching the extracellular surface 
(GrandPre et al., 2000). 
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FIGURE 5.6. Nogo-A protein expression in cultured olfactory ensheathing cells (OECs) and 
oligodendrocytes (OLGs) permeabilised with Triton X-100. 
lmmunofluorescence staining for Nogo-A protein in OECs (A) and OLGs (D). Nogo-A was detected 
in OECs only after permeabilisation with Triton X-100. Both cells types were counterstained with Nuclear 
Yellow (B and E). Controls in which the primary antibody was omitted were negative for both cell types (C 
and F). Scale bar, lOOµm . 
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FIGURE 5.7. Lack of Nogo-A protein expression in unpermeabilised Olfactory Ensheathing Cells 
(OECs). 
Unpermeabilised OECs showed negative staining for Nogo-A (A) when compared with controls in 
which the primary antibody was omitted (B). Cells were double labeled with Nuclear Yellow (C and D). 
Scale bar, lOOµm 
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5.4. Discussion 
The results of this study indicate that OECs express the inhibitory molecule Nogo 
and its receptor NgR. The expression pattern of Nogo transcripts appears to alter when 
OECs are implanted into the injured spinal cord. This provides further support for the 
theory that OEC phenotype is influenced by soluble factors intrinsic to the injured spinal 
cord and reflects their capacity for antigenic plasticity. 
Cultured OECs, OLGs, SCs and ASTs were found to express Nogo-A, -B and -
ABC mRNA transcripts. However one puzzling observation was that the sum of Nogo-
ABC did not equal the sum of Nogo-A, Nogo-B (measured) artd any Nogo-C (not 
measured) in each cell type (see Table 5.2). There are two possibilities that could account 
for this observation. First, each primer set amplified a separate region of the nogo gene 
hence their amplification efficiencies could vary. As a result of this Nogo-A, -B and -
ABC levels were not compared within the same cell type. Second, because Nogo-C 
expression was not measured it is possible that any fluctuations in Nogo-C could be 
reflected in the Nogo-ABC level. 
Cultured OECs, SCs and ASTs also expressed mRNA for the NgR, which was not 
detected in OLGs. The finding that SCs and ASTs express the NgR is in contrast to 
previous reports (Josephson et al., 2001; Huber et al., 2002; Josephson et al., 2002). This 
apparent discrepancy could be due to the different techniques used in the previous 
studies. To confirm these findings immunocytochemical analysis of Nogo-A and NgR 
was performed on OECs in vitro. Olfactory ensheathing cells were positive for the Nogo-
A protein (which was found to be intracellular), but negative for the NgR protein. 
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Implantation of encapsulated OECs into the injured spinal cord resulted in a 
significant increase in Nogo-A, and Nogo-B and a decrease in Nogo-ABC mRNA 
expression when compared with encapsulated OECs maintained in vitro. These changes 
may have been due to up- or down-regulation of Nogo in response to unknown injury 
associated factors. Because the effects of very few lesion-induced factors have been 
described for OECs it is not known which of these specifically influenced Nogo 
expression. 
It was notable that NgR mRNA was present in cultured OECs in flasks but was not 
detected when the cells were encapsulated, either in vitro or when implanted. The 
underlying reasons for this are unclear, but observations from light and scanning electron 
microscopy suggest that there were distinct differences in the morphology between OECs 
cultured in flasks and those encapsulated. When cultured in flasks OECs flatten and 
elaborate processes (Vincent et al., 2003), but when placed in capsules many of them 
assume a round morphology (see chapter three). The difference in morphology could 
reflect a physiological difference possibly in the expression of cell membrane associated 
molecules such as the NgR. 
Previous reports have shown that Nogo and its receptor NgR are present within the 
olfactory system (Josephson et al., 2001; Josephson et al., 2002; Tozaki et al., 2002). 
Nogo-A and Nogo-ABC were detected in the OB of fetal rats although no data regarding 
expression in neonatal or adult animals have been reported (Josephson et al., 2001). The 
NgR is expressed in the OB during embryonic development and in the adult mouse where 
it was localised to neurons of the mitral cell layer (Josephson et al., 2002). This may 
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suggest that Nogo plays an important role in restricting growth and plasticity in the 
developing olfactory system. 
Schwann cells like OECs promote axonal growth and until now were thought not to 
express Nogo (Josephson et al., 2001). However an early report showed that IN-1 
antibody staining (against Nogo) produced a similar distribution pattern to that of MBP 
and MAG, which are known to be expressed by SCs (Rubin et al., 1994). Furthermore it 
was demonstrated that MBP, MAG and IN-1 stained the sciatic nerve in which SCs 
reside. However IN-1 staining was observed only after pre-fixation of sciatic nerve tissue 
with formaldehyde (Rubin et al., 1994). Since then several studies have confirmed that 
Nogo-A, Nogo-B and Nogo-C are present within the sciatic nerve (Chen et al., 2000; 
GrandPre et al., 2002; Huber et al., 2002). Given that Nogo is present in SCs its 
expression in the sciatic nerve could be attributed at least in part to the presence of SCs. 
The predicted topology of the Nogo protein suggests that there are two hypothetical 
means by which neurite inhibition could occur. Firstly the neurite growth inhibitory 
Nogo-66 domain was thought to be exposed to the extracellular surface (GrandPre et al., 
2000) and secondly an inhibitory region in the N-terminus could potentially be located 
extracellularly (Chen et al., 2000). Recent studies of the Nogo-A protein have revealed a 
I 
third possible inhibitory domain within the Nogo-A specific exon 3 (Oertle et al., 2003b ). 
However there have been several studies suggesting that N ogo is primarily located 
intracellularly (Josephson et al., 2001; Taketomi et al., 2002; Jin et al., 2003). This is 
consistent with the finding that Nogo-A in OECs was detected only after permeabilisation 
of the cell membrane suggesting that it is intracellular. However in OLGs Nogo-A could 
be detected with or without permeabilisation of the cell membrane suggesting that the 
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protein is both intra- and extracellular. In contrast another study has shown that OLGs 
express Nogo in their cytoplasm but not on their plasma membrane or in the myelin 
sheath they produce (Taketomi et al., 2002). 
At the present time we cannot rule out the possiblility that OEC-derived Nogo is 
inhibito~ to axonal growth. It could be that these cells simply produce or secrete levels 
of Nogo that are well below that required to exert an inhibitory effect. Hence Nogo 
function could be dose-dependant whereby high levels inhibit growth and low. levels 
restrict plasticity or alternatively have no noticeable effect. Similarly the inhibitory 
effects of OEC Nogo may be dependant upon its release into the extracellular 
environment as suggested for OLGs (Goldberg and Barres, 2000; GrandPre et al., 2000). 
Many studies of Nogo function have focused on the inhibitory activity of Nogo-A 
expressed by OLGs and how this can be neutralized by application of the antibody IN-1 
(Bregman et al., 1995; Brosamle et al., 2000). Recent studies suggest that Nogo 
expressed by OECs could have functional roles unrelated to those already identified. 
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CHAPTER SIX 
Summary and Future Directions 
6.1. Summary and Future Directions 
In summary this study provides evidence that the injured spinal cord influences the 
morphology and gene expression of transplanted OECs. This study provides further 
support for the notion that OECs are an extremely plastic cell type and that this may 
underlie their ability to promote the growth of injured axons. In this section future 
experiments are proposed to address some of the uncertainties raised by these 
experiments well as new projects that can be initiated to investigate other areas. 
In addition to the experiments proposed in chapter three, a more complete picture of 
OEC plasticity after implantation may be gained by including more control groups in the 
scanning electron microscopy (SEM) and real-time RT-PCR analyses. By implanting 
OEC-filled capsules near the uninjured as well as injured spinal cord the effect of both 
injury-associated factors and factors intrinsic to the spinal cord itself on OEC phenotype 
could be examined. Any differences between OECs in these two groups would be 
attributable to the presence of injury-associated factors. 
By implanting empty capsules into the injured and uninjured spinal cord the influx 
of contaminating cells could be investigated. Comparison of empty capsules with the 
corresponding OEC-filled capsules from injured and uninjured spinal cord may have 
assisted with the identification and morphological analysis of OECs. Similarly any 
contribution by cellular contaminants to the gene expression profile of OECs from the 
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injured and uninjured spinal cord could be accounted for by subtracting the empty 
capsule values from the OEC-filled capsule values. In effect the resultant expression 
values may then be a better reflection of the presence of OECs not of contaminating cells. 
Due to the growth promoting nature of OECs it was not expected that they would 
express Nogo and its receptor NgR. In contrast the presence ofNogo and the NgR in the 
developing olfactory system (Josephson et al., 2001; Josephson et al., 2002; Jin et al., 
2003) along with the finding that p75NTR acts as part of a signaling complex with the NgR 
(Wang et al., 2002a) may indicate a role for expression of Nogo and NgR in OECs. In 
this study cultured OECs, SCs and ASTs were shown to express mRNA for Nogo and its 
receptor NgR. Moreover implantation into the injured spinal cord significantly increased 
the levels of Nogo-A and -B in OECs. The Nogo-A protein was also located 
intracellularly in OECs, although the NgR protein could not be detected. 
Future studies will be necessary to investigate the presence ofNgR protein in OECs 
in vitro. This could be assesed using different culture media and/or supplements to induce 
expression of the NgR. For example in a previous study morphological change was 
induced in OECs by addition of the membrane permeant cAMP analogue dibutyryl 
cAMP (dBcAMP) to serum-containing medium (Vincent et al., 2003). Similarly the 
effects of some growth factors on OECs in serum-containing medium can be potentiated 
by addition of the intracellular cAMP raising agent forskolin (FSK) (Yan et al., 2001 b ). 
Both dBcAMP and FSK are thought to exert their effects via activation of Rho-A and its 
downstream signalling cascade. Furthermore cultured SCs have been shown to proliferate 
in reponse to PDGF only when cultured in the presence of intracellular cAMP raising 
agents a response that has been attributed to a cAMP-mediated PDGF receptor 
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upregulation (Weinmaster and Lemke, 1990). Since the effects of Nogo are mediated by 
activation of Rho-A (Niederost et al., 2002; Fournier et al., 2003) which in tum is 
regulated by cAMP, addition of dBcAMP or FSK to OECs in vitro could potentially 
induce expression of the NgR. 
If the presence of the NgR in OECs could be confirmed the effect ofNogo proteins 
on OECs and perhaps also SCs could be assessed by a series of in vitro assays. Cell 
morphology could be examined by light and scanning electron microscopic analysis of 
cells treated with different concentrations of Nogo-A, -B or -C protein compared with 
untreated cells. Similarly antigenic phenotype after treatment with Nogo-A, -B or -C 
proteins could be examined by immunofluorescence staining of treated and untreated 
cells for common OEC and SC markers (such as S-100, p75NTR, N-CAM, Po and GFAP) 
and/or growth factor proteins (including GGF, BDNF, GDNF, NDF and CNTF). 
Proliferation could also be investigated by measuring bromodeoxyuridine uptake (BrdU) 
in Nogo-A, -B and -C treated cells compared with untreated cells. Such experiments 
would provide a starting point for a more intensive analysis of the role.ofNogo in OECs 
and SCs. 
The presence ofNogo in OECs opens up a new avenue of research. The function of 
Nogo in the olfactory system could be examined using Nogo deficient knockout (KO) 
mice. If Nogo plays a role in olfactory axon outgrowth any abnormalities could be 
identified by histology and/or immunohistochemistry of tissue sections from the olfactory 
systems of both adult and embryonic KO mice. Similarly the effects of the different 
isoforms on olfactory system development could be examined in mice deficient in a 
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single Nogo isoform. The olfactory system of Nogo KO mice would also provide a 
unique environment for investigating the role ofNogo in axonal growth after injury. 
Because Nogo is inhibitory to axonal growth and plasticity its role in growth 
promoting cell types, such as OECs and SCs is unclear. Yet its location in OECs could be 
indicative of an unknown intracellular role. In fact a recent study has proposed a novel 
function for Nogo in vascular remodelling in particular for the enhanced migration of 
endothelial cells (Acevedo et al., 2004). Similarly another study reported that neurons of 
the sciatic nerve and spinal cord express Nogo-A mRNA and protein both before and 
after injury (Hunt et al., 2003) suggesting that Nogo-A expression does not necessarily 
correlate with a lack ofregenerative potential. 
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